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  Skeletal muscle is highly conserved among vertebrates and is essential for strength and 
locomotion. This tissue becomes integrated with the skeletal system via tendons at the 
myotendinous junction and with the nervous system at the neuromuscular junction. Both of 
these specialized junctions are rich in extracellular matrix, a protein scaffold that occupies the 
extracellular space of cells. Skeletal muscle is also highly plastic and can grow in size 
(hypertrophy) or lose mass (atrophy) in response to genetic or environmental cues. Muscle 
atrophy is found in individuals battling a number of neuromuscular conditions, including 
muscular dystrophy. 
 Muscular dystrophies are a suite of incurable genetic diseases characterized by 
progressive muscle wasting and weakness. Secondary dystroglycanopathies are a subset of 
muscular dystrophies that result from mutations in genes that participate in Dystroglycan 
glycosylation. This process is necessary in order for muscle fibers to interact with the 
extracellular matrix and connect to nearby tendons and/or nerves. Patients battling secondary 
dystroglycanopathies experience a wide array of symptoms and severities, even when the 
 
 
molecular basis of their condition is identical. This prevents doctors and clinicians from 
providing patients and their families with accurate prognoses. 
Multiple roadblocks in our understanding of secondary dystroglycanopathies exist. We 
previously determined that improving muscle-extracellular matrix adhesion with NAD+ 
supplementation is sufficient to improve muscle structure in primary dystroglycanopathy. 
However, it is unknown whether this strategy is applicable to secondary dystroglycanopathies. It 
is also unknown how identical molecular variants of an allele can result in phenotypic variation 
among individuals with these conditions. Here, we leverage the zebrafish model system to 
address these gaps. We find that NAD+ supplementation prior to muscle development improves 
muscle structure in an established zebrafish model of secondary dystroglycanopathy, as well as 
myotendinous junctions and neuromuscular junctions. Additionally, we show that a new 
zebrafish model of secondary dystroglycanopathy exhibits phenotypic variation and plasticity 
throughout the first several days of life and is not improved by NAD+ supplementation. These 
studies highlight the importance of viewing secondary dystroglycanopathies as individual 
conditions at both the basic and clinical levels. 
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CHAPTER 1 
MECHANISMS OF MUSCLE DEVELOMPENT AND DISEASE 
1.1 Introduction  
Many of the organisms inhabiting planet Earth possess muscle, a highly conserved tissue 
that contributes to strength and locomotion. Muscle can be divided into three subtypes: cardiac, 
smooth, and skeletal. In vertebrates, skeletal muscle is associated with organismal locomotion 
and connects to bones via tendons. It is composed of multinucleated fibers that happen to be 
some of the largest cells in our bodies. While there are multiple forms of these fibers, the two 
primary types are slow-twitch muscle fibers that are responsible for endurance and fast-twitch 
fibers that are associated with speed. Regardless of subtype, all skeletal muscle fibers contain 
actin and myosin filaments that contribute to muscle contraction (Goody et al., 2017; Hinits and 
Hughes, 2007).  
Skeletal muscle relies on other tissues in the body in order to properly develop, 
function, and maintain homeostasis. It becomes integrated with the skeletal system via tendons 
at myotendinous junctions (MTJs) and with the nervous system at neuromuscular junctions 
(NMJs). These specialized junctions help achieve proper architecture, function, and homeostasis 
in skeletal muscle and are rich in extracellular matrix (ECM) (reviewed by (Goody et al., 2015)). 
The ECM is a scaffold of proteins that occupies the extracellular space of cells and associates 
with muscle fibers through cell-matrix adhesion complexes. Additionally, skeletal muscle is 
highly plastic, meaning that it is susceptible to change based on genetic and/or environmental 
input. Skeletal muscle has the ability to grow in size (hypertrophy) in response to exercise and 
diet. Conversely, muscle atrophy—or wasting—can occur as a consequence of aging, cachexia, a 
lack of exercise, or neuromuscular diseases. Additionally, the degree to which individuals 
battling conditions that affect muscle tissue can regenerate skeletal muscle is highly variable. 
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 Neuromuscular diseases are disorders that impair muscle and/or peripheral nerve 
function. These conditions are prevalent in humans, and some notable examples include 
congenital myasthenic syndrome, a genetic disorder of the NMJ, and muscular dystrophies, a 
suite of heritable diseases associated with progressive muscle wasting and weakness. Muscular 
dystrophies vary remarkably in terms of the genetic basis, age of onset, severity, and muscle 
groups affected. Patients battling the same subtype of muscular dystrophy sometimes 
experience drastically different symptoms and severities, even when the molecular basis of their 
condition is identical.  
 Several roadblocks in our understanding of muscle development and disease currently 
exist. The adhesion of muscle fibers to the ECM is disrupted in several forms of muscular 
dystrophy. Recent work suggests that improving muscle cell-matrix adhesion his beneficial for 
some of these conditions. In particular, it has been shown that increasing levels of functionally 
redundant receptors can compensate in the absence of others (Goody et al., 2012; Sarathy et 
al., 2017). However, it is necessary to determine the breadth at which this strategy is applicable. 
Chapter 2 describes a study that addresses this in a zebrafish muscular dystrophy model that has 
not been examined in this context. We determined that one previously described method of 
enhancing cell-ECM adhesion improves muscle structure and function, as well as MTJ and NMJ 
morphology. However, another previously described method of improving muscle structure has 
a neutral effect in this model. These studies provide insight into how these specialized junctions 
are affected in dystroglycanopathies and highlight the importance of viewing different types of 
muscular dystrophies as individual conditions. 
 An additional gap in the field of muscle biology is understanding how phenotypic 
variation develops among individuals carrying the same disease-causing mutation. Although the 
disease-causing alleles of many forms of neuromuscular disease have been identified, the 
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unpredictable nature of some of these conditions prevents doctors and clinicians from providing 
patients and their families with accurate prognoses. Chapter 3 details a study that begins to 
address this gap. We engineered a zebrafish mutant by targeting a gene associated with 
neuromuscular phenotypic variation via CRISPR/Cas9 mutagenesis. These fish exhibit phenotypic 
variation and plasticity in muscle throughout the first several days of life. Given the idiosyncratic 
nature of many neuromuscular diseases, understanding the mechanisms behind phenotypic 
variation and plasticity can provide a valuable perspective on how to approach these conditions 
from a clinical lens. 
  Throughout my graduate training in biomedical science, I learned that understanding 
the basic biology of muscle homeostasis is key to creating an environment conducive to optimal 
muscle health. Although it is important to consider how muscle development and homeostasis 
relates to muscle disease, providing a baseline for translational research requires an 
understanding of the proteins, cellular structures, and neighboring tissues that work in concert 
to orchestrate muscle homeostasis. The overarching goal of my doctoral dissertation research 
was to leverage the zebrafish model system to answer questions regarding cell-matrix adhesion, 
neuromuscular development, and phenotypic variation in zebrafish models of muscle disease. 
1.2. Structure and function of the myomatrix 
  Skeletal muscle is necessary for strength and locomotion and is comprised of bundles of 
individual muscle fibers. Although the muscle fibers themselves are critical for homeostasis of 
this organ, they must adhere to their surrounding extracellular matrix (ECM) to achieve 
homeostasis. Muscle-associated ECM, or the myomatrix, is composed of a vast array of 
extracellular proteins that link to structures within the muscle cell via transmembrane receptors 
(Fig. 1.1A). The myomatrix provides structure and mediates bidirectional signaling between cells 
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and their microenvironments (Goody et al., 2015). These attributes are important for skeletal 
muscle, given its recurrent cycles of tension, contraction, and relaxation.  
  One specialized myomatrix component that is important for structural integrity and 
signaling is the basement membrane. Basement membranes surround muscle fibers and contain 
the fibrous proteins collagen-IV and laminin (Goody and Henry, 2010; Goody et al., 2015). 
Laminin is composed of three types of chains that trimerize to form a complete heterotrimeric 
protein (Miner and Yurchenco, 2004). The specific chains include five alpha, four beta, and three 
gamma chains (Miner and Yurchenco, 2004). Different combinations of laminin heterotrimers 
associated with different developmental stages and/or physiological structures. For example, 
laminin-111 (lamininalpha1beta1gamma1) is primarily expressed during early muscle 
development (Gullberg et al., 1999) and is later replaced by laminin-211 
(lamininalpha2beta1gamma1) (Sasaki et al., 2002). Mutations in LAMA2, which encodes the 
lamininalpha2 chain, are associated with merosin-deficient muscular dystrophy (MDC1A) 
(Helbling-Leclerc et al., 1995). Therefore, lamininalpha2 is important for muscle homeostasis 
and cell-matrix adhesion. 
  But how do laminins interact with muscle? Laminin interacts with two types of 
transmembrane receptor complexes that connect muscle fibers to their surrounding 
microenvironments. The integrin heterodimers are one of these receptor complexes. Integrin 
heterodimers are composed of alpha and beta subunits and possess three distinct 
conformations—active, inactive, and ligand-bound (Askari et al., 2009). Extracellularly, integrin 
complexes have different ligands within the myomatrix, depending on the specific heterodimer. 
For example, integrinalpha5beta1 serves as a receptor for fibronectin, whereas 
integrinalpha6beta1 and integrinalpha7beta1 are receptors for laminin (Fig. 1.1A) (Goody et al., 
2015). Different integrin complexes are more prevalent at different stages of an organism’s life. 
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Figure 1.1. Structure of the myomatrix. (A) Schematic depicting adhesion complexes that link 
the actin cytoskeleton of muscle fibers with basement membranes that are rich in laminin and 
collagen IV. (B) The myomatrix (tan chains) surrounds the entirety of muscle tissue, bundles of 
muscle fibers, and individual fibers (blue). The myotendinous junction (MTJ) and neuromuscular 
junction (NMJ) link muscle fibers to tendons (gray) and nerves (black) respectively. The MTJ and 
NMJ interact with muscle fibers via cell-ECM interactions. Originally from Goody et al., 2015. 
 
 
 
Integrinalpha6beta1 is the prevailing isoform throughout early muscle development and 
interacts with laminin-111 (Bajanca et al., 2006; Bronner-Fraser et al., 1992), whereas 
integrinalpha7beta1 is the major laminin-binding integrin isoform in mature skeletal muscle 
(Burkin and Kaufman, 1999) and interacts with laminin-211 (Holmberg and Durbeej, 2013). Loss 
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of integrinalpha7 is associated with muscular dystrophy (Hayashi et al., 1998; Mayer et al., 
1997); thus, functional integrinalpha7beta1 heterodimers are essential for muscle homeostasis.   
  In addition to integrin receptor complexes, the dystrophin and utrophin glycoprotein 
complexes (DGC and UGC) also connect the actin cytoskeleton of muscle fibers to the laminin-
rich basement membrane in the myomatrix (Fig. 1.1A) (Ervasti and Campbell, 1993). The DGC 
contains dystrophin and is predominantly at the myotendinous junction (Ervasti and Campbell, 
1993), whereas the UGC is predominantly found at the neuromuscular junction (Deconinck et 
al., 1997). These complexes also contain Sarcoglycan, Sarcospan, and Dystroglycan (Michele and 
Campbell, 2003). Dystroglycan (DG) is a major component of this complex and contains a 
transmembrane beta subunit and an extracellular alpha subunit. This alpha subunit serves as a 
receptor for laminin, perlecan, neurexin, and agrin (Michele and Campbell, 2003). The alpha 
subunit of DG binds to these ECM proteins when it is glycosylated by a team of enzymes that 
synthesize a glycan ligand for these proteins (detailed in Section 1.3). Given that the DGC is 
necessary for muscle fibers to anchor to their extracellular environments, proper assembly of 
the DGC is critical for muscle development and homeostasis.  
  The adhesion complexes that establish connections between muscle fibers and their 
extracellular environments are functionally redundant in their role of indirectly connecting the 
actin cytoskeleton of the myomatrix (Goody et al., 2012). These complexes are also critical for 
linking muscle fibers to two specialized junctions—the myotendinous junction (MTJ) and the 
neuromuscular junction (NMJ). These specialized junctions are rich in ECM and connect muscle 
tissue to nearby tendons and nerves respectively (Goody et al., 2015) (Fig. 1.1B). The following 
subsections will describe both of these regions in greater detail.  
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1.2.1. May the force be with you: ECM components of the myotendinous junction 
  Tendons provide an essential connection between skeletal muscle and bone that 
facilitates locomotion. While tendons themselves serve a bridge between muscle and bone, the 
region connecting muscle to tendons is known as the myotendinous junction (MTJ). This 
specialized junction is a structural unit that consists of extracellular matrix proteins, 
transmembrane receptors, and sarcolemma (the transmembrane region of muscle fibers) and 
extends to the cytoskeleton. On the muscle end, the actin cytoskeleton is indirectly linked to 
transmembrane proteins that interact with ECM components (Goody et al., 2017). On the 
tendon side, tenocytes (tendon cells) produce collagen fibers that connect to the rest of the 
ECM (Charvet et al., 2012). The MTJ is a critical structural component of muscle and is the major 
site of force transmission (Charvet et al., 2012) that helps muscle contraction drive movement. 
  Several well-known ECM components are enriched at the MTJ. Collagen-I and tenascin 
are highly concentrated on the tendon side of the junction, collagen-VI is distributed throughout 
the myomatrix and provides structural stability of the sarcolemma during muscle contraction, 
and laminin and collagen-IV are abundant in the muscle basement membrane (Charvet et al., 
2012; Goody et al., 2015). Throughout development, MTJ undergoes changes in composition, 
especially in zebrafish. For example, fibronectin is initially present at somite boundaries, but 
eventually becomes downregulated (Snow and Henry, 2009). An increase in laminin-111 at the 
MTJ correlates with fibronectin downregulation (Jenkins et al., 2016; Snow et al., 2008a). A shift 
from laminin-111 expression to laminin-211 expression also occurs at the MTJ in zebrafish, mice, 
and humans, and laminin-211 then remains the prevailing laminin isoform at the MTJ (Charvet 
et al., 2012; Goody et al., 2017). 
  Several additional ECM components play important roles in MTJ maintenance. Collagen-
VI is distributed throughout the myomatrix and provides the sarcolemma with structural 
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stability throughout muscle contraction (Telfer et al., 2010). Thrombospondins bind to 
transmembrane receptors and ECM proteins to mediate cell-matrix adhesion (Charvet et al., 
2012). In Drosophila, thrombospondin is synthesized and secreted by tenocytes and binds to 
muscle-specific integrin receptors (Subramanian et al., 2007). Zebrafish thrombospondin4b 
(tsp4b) is critical for basement membrane assembly in tendons and for muscle attachment 
during MTJ development and repair (Subramanian and Schilling, 2014). Deficiencies of ECM 
components that participate in MTJ development and homeostasis are linked to aberrant 
muscle development (Hall et al., 2007; Odenthal et al., 1996; Snow et al., 2008a; Subramanian 
and Schilling, 2014; Telfer et al., 2010; Welser et al., 2009). Therefore, appropriate timing and 
expression of these proteins is critical for MTJ development and homeostasis.  
1.2.2. Communication breakdown: ECM components of the neuromuscular junction 
 In addition to muscle tissue and MTJs, locomotion also depends on the initiation and 
regulation of muscle contraction from nerves. This occurs via the neuromuscular junction (NMJ), 
a synapse that lies at the interface of motoneurons and muscle fibers. Motoneurons that 
innervate muscle fibers serve as the presynaptic component and release neurotransmitters. In 
vertebrates, acetylcholine is the neurotransmitter that is released, which travels to post-
synaptic acetylcholine receptors (AChRs) on the surface of muscle cells (Singhal and Martin, 
2011). Formation of the vertebrate NMJ relies on careful crosstalk of initial muscle and 
motoneuron development. Embryonic muscle fibers are prepatterned with aneural AChRs in the 
medial regions of muscle prior to innervation, the motoneuron migrates to the muscle fiber for 
innervation, and synaptogenesis occurs (reviewed by (Burden et al., 2018; Tintignac et al., 2015; 
Wu et al., 2010)). This process in zebrafish can be studied in the context of slow-twitch and fast-
twitch muscle fibers (discussed in Section 1.5.1). 
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 Vertebrate NMJ development and homeostasis also relies on myomatrix components 
and their receptors. Muscle fibers secrete and deposit laminin and collagen IV, the two primary 
basement membrane proteins, into the synaptic cleft to form a basement membrane that 
provides a barrier between the presynaptic motoneuron and the postsynaptic muscle fiber 
(Singhal and Martin, 2011). The synaptic laminins that are prevalent at the NMJ are distinct from 
those that are prevalent at the MTJ and include the lamininbeta2 chain. These laminins include 
laminin-221 (lamininalpha2beta2gamma1), laminin-421 (lamininalpha4beta2gamma1), and 
laminin-521 (lamininalpha5beta2gamma1) (Singhal and Martin, 2011). The NMJ also contains 
several additional and transmembrane components that are indispensable for NMJ 
development and maintenance and have been nicely reviewed (Pilgram et al., 2010; Singhal and 
Martin, 2011; Tintignac et al., 2015; Wu et al., 2010). Agrin is a heparin sulfate proteoglycan 
(HSPG) protein in the ECM that contributes to AChR clustering and NMJ stabilization, and neural 
agrin is secreted by motoneurons and released into the basement membrane (Pilgram et al., 
2010; Singhal and Martin, 2011; Tintignac et al., 2015; Wu et al., 2010). Agrin interacts with 
several receptors on the post-synaptic membrane, including alpha-DG, muscle-specific receptor 
tyrosine kinase (MuSK), and the agrin co-receptor Lrp4 (Pilgram et al., 2010; Singhal and Martin, 
2011; Tintignac et al., 2015; Wu et al., 2010). MuSK is necessary for AChR prepatterning and 
post-synaptic differentiation, is activated by the protein Dok7, and interacts with rapsyn, leading 
to MuSK signaling (Singhal and Martin, 2011; Tintignac et al., 2015). Thus, MuSK is an especially 
critical contributor to NMJ development and homeostasis. 
 Proper coordination between muscle, motoneurons, and the signaling components that 
contribute to AChR clustering and maintenance is key for NMJ assembly and function. 
Autoantibodies against AChRs, MuSK, and Lrp4 are associated with autoimmune myasthenia 
gravis, a progressive NMJ disease, in human populations (Pevzner et al., 2012). Studies have also 
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detected NMJ abnormalities in mouse models of muscular dystrophies. These include Duchenne 
Muscular Dystrophy (Pratt et al., 2015), the most well-known form of the disease, as well as 
muscular dystrophies associated with compromised DG (Herbst et al., 2009; Saito et al., 2007). 
Chapters 2 and 3 will discuss how the NMJ is disrupted in zebrafish models of 
dystroglycanopathy.  
1.3. Post-translational modification of Dystroglycan 
  As detailed in Section 1.2, the dystrophin glycoprotein complex (DGC) is a major 
receptor complex that connects the actin cytoskeleton of muscle fibers to the laminin-rich 
basement membrane in the myomatrix (Ervasti and Campbell, 1993). Major components of this 
complex include dystrophin that is linked to f-actin and DG. Several muscular dystrophies are 
associated with mutated components of the DGC. Mutations in Dystrophin, the intracellular 
component of the DGC, are associated with Duchenne and Becker Muscular Dystrophies. 
Compromised DG is associated with a broad suite of muscular dystrophies known as 
dystroglycanopathies. 
  DG serves as a major receptor for a number of ECM proteins, including laminin. Like 
many other components of the ECM and/or the neuromusculoskeletal system, a-DG is heavily 
glycosylated. This process is necessary in order for interact with laminin and other ECM proteins 
that are involved in cell-matrix adhesion. Multiple enzymes work in concert to synthesize this 
glycan (Fig. 1.2) (reviewed by (Nickolls and Bönnemann, 2018; Taniguchi-Ikeda et al., 2016). 
DOLK, GMPPB, DPM1, DPM2, and DPM3 help synthesize dolichol phosphate mannose 
precursors used in o-mannosylation reactions (Carss et al., 2013; van Tol et al., 2019). When co-
expressed, POMT1 and POMT2 use these precursors to add mannose (o-linked) directly 
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Figure 1.2. Post-translational modification of alpha-Dystroglycan. (A) Multiple enzymes work 
together to synthesize a glycan chain that links alpha-DG (light blue) to ECM proteins such as 
laminin. This process is important for muscle-ECM adhesion. FKRP and GMPPB (bold font) will be 
the focus of subsequent chapters in this dissertation. (B) Legend for molecules depicted in (A). 
Adapted from Carss et al. (2013), Nickolls and Bönnemann (2018), Taniguchi-Ikeda et al., 2016, 
and van Tol et al. (2019). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to alpha-DG (Manya et al., 2004). N-acetylglucosamine is subsequently added to mannose via 
POMGNT1 and POMGNT2 (Ogawa et al., 2013; Yoshida et al., 2001), and the mannose modified 
by POMGNT2 is phosphorylated by POMK (Yoshida-Moriguchi et al., 2013). B3GALNT2 adds N-
acetylgalactosamine to the N-acetylglucosamine synthesized by POMGNT2 (Yoshida-Moriguchi 
et al., 2013). ISPD then supplies CDP-ribitol that is used by FKRP and FKTN to produce a tandem 
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ribitol 5-phosphate repeat (Gerin et al., 2016; Kanagawa et al., 2016). TMEM5 then catalyzes the 
addition of xylose (Praissman et al., 2016), followed by the addition of glucuronic acid by 
B4GAT1 (Willer et al., 2014). Finally, LARGE synthesizes a repeating unit of xylose and glucuronic 
acid that serves as the ligand for laminin (Inamori et al., 2012). Completion of this process in the 
appropriate steps is necessary for muscles to adhere to their extracellular environments and 
achieve homeostasis. Failure of DG to undergo glycosylation is associated with a complex subset 
of muscular dystrophies known as secondary dystroglycanopathies. 
1.4. The many faces of dystroglycanopathies 
  The dystroglycanopathies are a group of molecularly distinct muscular dystrophies that 
are associated with compromised DG function. Primary dystroglycanopathy occurs with 
mutations in DG (Frost et al., 2010; Hara et al., 2011), whereas secondary dystroglycanopathies 
occur due to mutations in genes that encode enzymes that participate in alpha-DG glycosylation 
(Muntoni et al., 2011). A number of molecularly distinct secondary dystroglycanopathies have 
been identified (Nickolls and Bönnemann, 2018); however, the clinical presentation of these 
conditions is highly variable, even when the disease-causing allele is known. While some 
individuals with secondary dystroglycanopathies experience limb-girdle muscular dystrophies 
that are more likely to develop in adolescence, others experience severe congenital muscular 
dystrophies (CMDs) (Muntoni et al., 2011). Individuals with CMDs associated with 
dystroglycanopathy often experience eye and/or brain involvement in the form of Muscle-Eye 
Brain Disease, Walker-Warburg Syndrome, or Cobblestone Lissencephaly (Nickolls and 
Bönnemann, 2018). This level of variation prevents clinicians from providing their patients with 
accurate prognoses. Poor understanding of the basic biological mechanisms of phenotypic 
variation and plasticity in neuromuscular diseases are a major roadblock to understanding 
13 
 
phenotypic variation in the dystroglycanopathies. Chapter 3 describes a study regarding 
phenotypic variation in new zebrafish dystroglycanopathy model. 
1.4.1. Fukutin-related protein (FKRP)  
 Fukutin-related protein (FKRP) participates in Dystroglycan (DG) glycosylation and is 
associated with dystroglycanopathy in humans (Brockington et al., 2001). As previously 
mentioned, FKRP is a ribitol-5 phosphate transferase that, along with Fukutin (FKTN), uses CDP-
ribitol to form a tandem ribitol-5-phosphate (Gerin et al., 2016; Kanagawa et al., 2016) that links 
N-acetylgalactosamine with xylose (Taniguchi-Ikeda et al., 2016). Failure of this linkage to form 
prevents completion of alpha-DG glycosylation, reducing its affinity to bind to ECM ligands such 
as laminin.  
 Like other dystroglycanopathies, patients harboring FKRP mutations present with 
phenotypic variability. Individuals with FKRP-associated dystroglycanopathy may develop limb-
girdle muscular dystrophy 2I (LGMD2I) or congenital muscular dystrophy with or without eye and 
brain involvement, depending on the specific molecular variant (Stensland et al., 2011; Van 
Reeuwijk et al., 2010). Although some genotype-phenotype correlation is present in patients 
with FKRP mutations (Beltran-Valero de Bernabé et al., 2004; de Bernabé et al., 2003; Stensland 
et al., 2011; Van Reeuwijk et al., 2010), there is sometimes phenotypic variation among 
individuals with identical mutations, particularly in regard to muscle pathology, levels of 
glycosylated alpha-DG, and age of onset (Stensland et al., 2011). This suggests genetic or 
environmental cues could contribute to disease progression in FKRP-associated 
dystroglycanopathy, as well as features other than muscle pathology and levels alpha-DG 
glycosylation.  
 Several animal models of FKRP-associated dystroglycanopathy have been engineered. 
These include Fkrp mutant mice (Ackroyd et al., 2009; Blaeser et al., 2013; Chan et al., 2010), 
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fkrp morphant zebrafish, (Kawahara et al., 2010; Lin et al., 2011; Thornhill et al., 2008), and fkrp 
mutant zebrafish (Serafini et al., 2018). Previous animal model have focused on levels of alpha-
DG glycosylation, regenerative capacity, and functional rescue. Gene therapy (Qiao et al., 2014; 
Thomas et al., 2016; Tucker et al., 2018; Vannoy et al., 2017) estrogen receptor modulators (Wu 
et al., 2018), and exogenous ribitol supplementation (Cataldi et al., 2018) improve muscle in 
mouse models. However, the efficacy of some therapies decreases if administered later in the 
mouse’s lifespan (Cataldi et al., 2018; Vannoy et al., 2017). This suggests that early intervention 
is most beneficial for these conditions. However, little is known regarding how MTJs and/or 
NMJs are affected in the context of FKRP deficiency. Chapter 2 describes the involvement of the 
MTJ and NMJ in a zebrafish model of FKRP-associated dystroglycanopathy and implicates early 
improvement of cell-matrix adhesion as a mechanism for improving muscle structure, function, 
and specialized muscle junctions. 
1.4.2. GDP-mannose pyrophosphyorylase B (GMPPB)  
 GDP-Mannose Pyrophosphorylase B (GMPPB) is an enzyme that synthesizes GDP-
mannose, a molecule used in several glycosylation reactions. In addition to O-mannosylation of 
alpha-DG, GMPPB also participates in GPI-anchor formation, N-glycosylation, and C-
mannosylation (Carss et al., 2013). Given that multiple myomatrix and NMJ proteins are also 
glycosylated, it is possible that GMPPB may have additional effects on neuromuscular skeletal 
system beyond alpha-DG modification. Unsurprisingly, mutations in GMPPB are associated with 
dystroglycanopathies that vary drastically in their clinical presentation.  
 Similar to FKRP-associated dystroglycanopathy, cases of congenital muscular 
dystrophies and limb-girdle muscular dystrophies (specifically Limb-Girdle Muscular Dystrophy 
Type 2T (LGMD2T)) have been documented in individuals harboring GMPPB mutations (Balcin et 
al., 2017; Cabrera-Serrano et al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al., 
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2017; Oestergaard et al., 2016; Raphael et al., 2014). Although molecular variants that 
specifically correlate with LGMD2T or congenital muscular dystrophies have been detected 
(Jensen et al., 2015), there is still a great deal of phenotypic variation in GMPPB-associated 
dystroglycanopathy. Additional conditions have been observed in patients with GMPPB 
mutations. Congenital myasthenic syndrome, a disease of the NMJ, has been detected in 
individuals harboring mutations with the same molecular basis as LGMD2T (Belaya et al., 2015; 
Luo et al., 2017; Montagnese et al., 2017; Rodríguez Cruz et al., 2016). Patients with the most 
common GMPPB mutation, c.79 G>C, have ranged between 2 and 62 years old at the age of 
symptomatic onset (Bharucha-Goebel et al., 2015; Montagnese et al., 2017). Cases of epilepsy 
and one case of autism spectrum disorder (Astrea et al., 2018; Raphael et al., 2014) have also 
been documented. These studies highlight the need to elucidate the mechanisms underlying 
phenotypic variation in GMPPB-associated dystroglycanopathy in order to accurately predict the 
course of the disease.  
  Given the poor genotype-phenotype correlation observed in these conditions, the fact 
that new individuals with GMPPB mutations are often identified (Sun et al., 2019), and the lack 
of genomic animal models for GMPPB-associated dystroglycanopathy, it is critical to study these 
conditions outside of the clinic. In terms of model systems, GMPPB mutations are linked with 
GMPPB mislocalization in cultured myoblasts, and gmppb morphant zebrafish have been 
superficially characterized and exhibit hypoglycosylated alpha-DG and muscle phenotypes (Carss 
et al., 2013). There are currently no published genomic models for this disorder in any model 
organism. Chapter 3 documents a study where a gmppb mutant was engineered to study the 
mechanisms underlying phenotypic variation in the dystroglycanopathies.  
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1.5. Zebrafish as a model organism for neuromuscular development and disease 
  Mammalian model systems have played a key role in elucidating the molecular and 
cellular biology of neuromuscular disorders. However, zebrafish (Danio rerio) offer many 
advantages for studying neuromuscular development and disease. Zebrafish embryos are 
externally fertilized and develop at a faster time scale than rodents. Embryonic and larval 
zebrafish are also optically transparent (Gibbs et al., 2013), which allows individuals to easily 
visualize their internal tissues under a fluorescence microscope, either through live imaging 
transgenics or with fixed immunostaining. This attribute allows one to easily image zebrafish 
muscle fibers, motoneurons, myotendinous junctions, and neuromuscular junctions throughout 
the embryonic and early larval stages. Other advantages of zebrafish as a model include high 
fecundity, low maintenance cost, and the ability to perform high-throughput screening in large 
numbers (Gibbs et al., 2013). Herein, the processes of neuromuscular development in zebrafish 
will be described, as well as current zebrafish models of muscular dystrophy and the emergence 
of CRISPR/Cas9 genome editing technology. 
1.5.1. Zebrafish neuromuscular development 
 Zebrafish muscle is organized into chevron-shaped segments called myotomes, which 
are derived from somites. Like mammals, zebrafish possess slow-twitch muscle fibers that are 
associated with endurance and fast-twitch muscle fibers linked to speed. Zebrafish muscle fibers 
can be divided into subtypes that can be identified by specific genetic markers: superficial slow-
twitch muscle fibers, slow-twitch muscle pioneers, medial fast-twitch muscle fibers, and fast-
twitch fibers (Wolff et al., 2003). In contrast to mammals, zebrafish subtypes of zebrafish muscle 
fibers spatially occupy distinct regions in the myotome (Goody et al., 2017). This allows for easy 
identification of each fiber type, as well as how it is affected in the context of muscle 
development and disease. 
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  But how does a zebrafish muscle segment with multiple fiber types develop? The 
paraxial mesoderm is initially segmented into somites. Somites are composed of four cell 
types—epithelial, mesenchymal, adaxial (slow-twitch fiber precursors), and anterior border 
cells—and give rise to multiple tissues, including muscle fibers, skeleton and tendon 
components, hematopoietic stem cells, and dermis of the skin (Goody et al., 2017). When 
muscle begins to develop, adaxial cells located in the medial plane of muscle elongate and 
subsequently migrate to the lateral surface of muscle (Devoto et al., 1996). This slow-twitch 
fiber migration induces fast-twitch muscle fiber morphogenesis (Henry and Amacher, 2004). 
These fast-twitch fibers elongate, and the terminal ends attach to the somite boundaries and 
form myotubes (Snow et al., 2008b). Muscle cell fusion occurs to form multinucleated muscle 
fibers (Powell and Wright, 2011). Finally, sarcomeres composed of thick myosin filaments and 
thin actin filaments are assembled into a myofibril that is essential for muscle contraction 
(Goody et al., 2017; Hinits and Hughes, 2007). All of these components must be actively 
maintained in order to achieve proper muscle homeostasis. 
  Motoneuron development and NMJ formation in zebrafish occurs simultaneously with 
muscle morphogenesis. Initially, fish muscle is innervated by the caudal (CaP), middle (MiP) and 
rostral (RoP) primary motoneurons (Myers et al., 1986). Secondary motoneurons follow similar 
innervation paths several hours later in development (Beattie, 2000; Fashena and Westerfield, 
1999). Medial slow-twitch muscle cells secrete ECM proteins that facilitate primary motoneuron 
guidance and exit from the neural tube (Guillon et al., 2016; Schweitzer et al., 2005). The medial 
slow muscle fiber precursors (adaxial cells) are prepatterned with aneural AChR clusters prior to 
the motoneurons reaching the choice point (Flanagan-Steet et al., 2005; Panzer et al., 2005). 
When the primary motoneurons leave the choice point, the CaP extends ventrally, the MiP 
extends dorsally, and the RoP remains in the middle of the myotome (Lewis and Eisen, 2003). 
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Initially, synapses form on muscle fibers located in close proximity to the choice point, followed 
by the medial muscle fibers, and are present in the lateral muscle by 48 hours post-fertilization 
(hpf) (Panzer et al., 2005). Chapters 2 and 3 both describe studies where fast-twitch muscle fiber 
innervation was quantified in zebrafish models of dystroglycanopathy.  
1.5.2. Modeling muscle disease in zebrafish 
 Over the past two decades, zebrafish have emerged as a valuable model for studying 
muscular dystrophies and other neuromuscular diseases. The optical transparency of zebrafish 
embryos allows one to easily observe zebrafish muscle through transgenic zebrafish or 
immunohistochemistry. Staining embryos for f-actin with fluorescently tagged phalloidin 
visualizes the zebrafish muscle fibers (Fig. 1.3A-C) and can detect several muscle abnormalities 
(Goody et al., 2017). Typically, zebrafish muscle fibers are organized into chevron-shaped 
muscle segments. When muscle undergoes appropriate development and maintenance, these 
fibers remain attached to the MTJ (Fig. 1.3A). In some cases, muscle fibers fail to be captured by 
the myotome boundary and extend past the MTJ. This phenomenon is known as MTJ failure 
(Fig. 1.3B) (Goody et al., 2017). At other times, muscle fibers detach from the boundaries, which 
is indicative of dystrophy (Fig. 1.3C). Damage to the sarcolemma may or may not accompany 
this fiber detachment (Goody et al., 2017). Therefore, both muscle and MTJ phenotypes at high 
magnification can be readily quantified in zebrafish models of muscle disease. This allows 
researchers to analyze muscle and MTJ abnormalities and delve into the mechanisms 
contributing to these phenotypes. 
 Compromised zebrafish muscle can also be detected via live, non-invasive birefringence 
imaging. This technique uses polarized light to detect muscle fibers that are in-tact and have 
maintained their integrity (Berger et al., 2012; Gibbs et al., 2013). Such fibers retain their 
birefringence and appear as well organized, bright muscle segments under polarized light    
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Figure 1.3. Visualization of zebrafish muscle phenotypes. (A-C) Anterior left, dorsal top, side-
mounted 48 hpf embryos stained for f-actin (phalloidin, gray) to visualize muscle fibers. (A) 
Control embryo. (B) Zebrafish embryo with fibers crossing the MTJ (MTJ failure, yellow 
arrowhead). (C) Zebrafish embryo with fiber detachment (dystrophy, white arrowhead). (D-E) 
Anterior left, dorsal top, side-mounted 4 dpf zebrafish imaged live for birefringence. (D) Control 
embryo with normal birefringence. (E) Embryo with muscle degeneration indicated by a patchy 
area of birefringence (blue arrowhead). 
 
 
 
 
 
 
 
(Fig. 1.3D). In contrast, patchy areas of birefringence are indicative of muscle damage (Fig. 1.3E) 
and reduced brightness indicates muscle fiber disorganization (Gibbs et al., 2013). This 
technique allows for rapid screening and quantification of muscle phenotypes (Berger et al., 
2012), particularly in regard to “mild,” “moderate,” or “severe” abnormalities in muscle 
development and homeostasis.  
 In addition to their visual advantages, zebrafish are also a suitable model for muscle 
disease at the genetic level. Many genes associated with the muscular dystrophies and other 
muscle diseases are conserved in zebrafish (Gibbs et al., 2013; Goody et al., 2017), making them  
an appropriate molecular model for the disease. A number of muscular dystrophies have been 
modeled in the fish by impairing expression of these genes, both with genomic manipulation 
and morpholino technology. Morpholinos are oligonucleotides that bind to RNA to block gene 
expression. Numerous morpholinos have been developed to target the transcripts of muscular 
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dystrophy genes (Carss et al., 2013; Guyon et al., 2003; Kawahara et al., 2010; Marchese et al., 
2016; Moore et al., 2008; Parsons et al., 2002; Postel et al., 2008; Roscioli et al., 2012; Stevens et 
al., 2013; Thornhill et al., 2008). However, there are disadvantages to using morpholinos. In 
particular, the effects of morpholinos often fade by 5 days post-fertilization (dpf) (Gibbs et al., 
2013). An alternative approach is to use zebrafish harboring genomic mutations for a gene of 
interest. Several zebrafish models of muscular dystrophy, including sapje (dystrophin mutants), 
candyfloss (lamininalpha2 mutants), and patchytail (dystroglycan mutants) were identified from 
ENU mutagenesis screens (Bassett and Currie, 2004; Gupta et al., 2011; Hall et al., 2007). 
Additionally, recent genome editing technology, including CRISPR/Cas9 mutagenesis, has yielded 
opportunities for researchers to generate mutations in the zebrafish genome with high 
specificity that can be used to generate new zebrafish muscular dystrophy mutants. 
1.5.3. CRISPR/Cas9 mutagenesis  
  Three prominent genome editing techniques—zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases TALENs, and CRISPR/Cas9—are commonly used in zebrafish and 
allow scientists to specifically target a region of genomic DNA. Although ZFNs and TALENS have 
been used extensively to generate mutant lines of interest (Rafferty and Quinn, 2018; Simone et 
al., 2018), CRISPR/Cas9 mutagenesis has recently gained popularity in the zebrafish community. 
CRISPR/Cas9 has garnered much attention—and some controversy—over the past several years. 
This technique emerges from the adaptive immune system of bacteria and archaea. Cas9 
enzyme derived from Streptococcus pyogenes or Streptococcus thermophilus accompanies 
clustered regulatory interspaced short palindromic repeat (CRISPR) RNAs (crRNAs) or single 
guide RNAs (sgRNAs) to target sites to cleave DNA (Cong et al., 2013; Gasiunas et al., 2012; Jinek 
et al., 2012; Mali et al., 2013). Specifically, the sgRNA-Cas9 complex is guided to a DNA sequence 
complementary to the sgRNA, and this sequence neighbors a protospacer adjacent motif (PAM) 
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sequence (Rafferty and Quinn, 2018). Double stranded breaks are induced that can later be 
repaired via two mechanisms: non-homologous end joining (NHEJ) and homology-directed 
repair (HDR) (Cornet et al., 2018; Liu et al., 2019). Over the past several years, multiple 
techniques for engineering CRISPR/Cas9 mutants in zebrafish have emerged and this technology 
continues to evolve (reviewed by (Cornet et al., 2018; Liu et al., 2019)). Chapter 3 describes a 
study where CRISPR/Cas9 mutagenesis was used to engineer a zebrafish model of GMPPB-
associated dystroglycanopathy. 
1.6. Concluding remarks 
  Skeletal muscle is important for strength and locomotion in vertebrate organisms. These 
muscle fibers adhere to surrounding ECM to form cell-matrix adhesion complexes. These 
connections help link muscle to nearby tendons and nerves, which contribute to its overall 
function. One of these complexes, the DGC is disrupted in secondary dystroglycanopathies, 
which are muscular dystrophies associated with progressive muscle wasting and weakness and 
phenotypic variation. It is currently unknown whether improving muscle cell-ECM adhesion is 
sufficient to improve muscle structure in secondary dystroglycanopathies. Chapter 2 describes a 
study that demonstrates that one of these strategies is sufficient prior to muscle development. 
It is also unknown how identical molecular variants of a GMPPB allele can result in phenotypic 
variation. Chapter 3 documents how we engineered an animal model of GMPPB-associated 
dystroglycanopathy that exhibits phenotypic variation and plasticity throughout the first several 
days of life. Both of these studies leverage the advantages of the zebrafish model system to 
answer questions regarding neuromuscular development and phenotypic variation in secondary 
dystroglycanopathies.  
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CHAPTER 2 
NAD+ IMPROVES NEUROMUSCULAR DEVELOPMENT IN A ZEBRAFISH MODEL  
OF FKRP-ASSOCIATED DYSTROGLYCANOPATHY 
2.1. Introduction  
  Muscle is a highly conserved tissue that part of the neuromusculoskeletal system and is 
essential for strength, locomotion, and health. The neuromuscular junction (NMJ) initiates 
muscle contraction, whereas the myotendinous junction (MTJ) is the major site of force 
transmission from muscle to the skeletal system. Muscle fibers adhere to their surrounding 
extracellular matrix (ECM), the MTJ, and the NMJ; and these adhesion complexes are critical for 
muscle development and homeostasis (reviewed by (Goody et al., 2015)). The muscle 
extracellular matrix and adhesion complexes at MTJs and NMJs are specialized and allow the 
muscle to adhere to and interact with neurons and tendons during development and 
homeostasis. Thus, regulation of cell-ECM adhesion is essential for development and 
homeostasis of the neuromusculoskeletal system. 
The dystrophin-glycoprotein complex (DGC) is an essential component of muscle-ECM 
adhesion. The DGC is a multi-protein complex that indirectly links the actin cytoskeleton of 
muscle fibers to the laminin-rich basement membrane in the ECM (Ervasti and Campbell, 1993). 
The DGC is thought to provide mechanical stabilization during muscle contraction (Ervasti and 
Campbell, 1993; Rybakova et al., 2000) in addition to its role as a signaling complex (Constantin, 
2014). Different variants of the DGC are present at the MTJ versus the NMJ. Whereas Dystrophin 
is the predominant protein that connects the actin cytoskeleton to the transmembrane protein 
Dystroglycan (DG) at the MTJ (Ervasti and Campbell, 1993), Utrophin mainly establishes this 
connection at the NMJ (Deconinck et al., 1997). Despite these differences, DG is present and 
highly glycosylated at both the MTJ and the NMJ. DG glycosylation is required for DG binding to 
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basement membrane proteins such as laminin, agrin, and perlecan (Briggs et al., 2016; Gee et 
al., 1994; Martin, 2006). Dystroglycanopathies result from mutations in genes responsible for 
glycosylation of alpha-DG (DG contains two subunits: a transmembrane beta subunit and an 
extracellular alpha subunit) (Godfrey et al., 2011; Inamori et al., 2012; Muntoni et al., 2011). 
Thus far, 16 gene products that participate in DG glycosylation have been identified (Nickolls 
and Bönnemann, 2018). In addition to muscle degeneration, dystroglycanopathies are 
frequently associated with central nervous system defects such as intellectual disability and 
brain malformation (Nickolls and Bönnemann, 2018). The role of DG glycosylation in the 
peripheral nervous system is less understood although abnormal NMJs have been reported after 
birth in a couple dystroglycanopathy mouse models (Côté et al., 1999; Herbst et al., 2009; 
Levedakou et al., 2005; Pratt et al., 2015; Saito et al., 2007). Because NMJ defects have been 
observed after embryonic development, the most prevalent hypothesis is that post-synaptic DG 
does not play a role in NMJ formation, but is important for NMJ stabilization (Nickolls and 
Bönnemann, 2018). For example, patients with mutations in GMPPB (required for GDP-mannose 
formation (Jensen et al., 2015)), show decreased action potentials with repeated nerve 
stimulation (Johnson et al., 2018). Given the plethora of glycosylated proteins at the NMJ, it is 
possible that a subset of dystroglycanopathy genes may be required outside of muscle tissue for 
NMJ development. 
  FKRP-associated dystroglycanopathy results from mutations in FKRP, which encodes an 
enzyme critical for DG glycosylation. FKRP works in concert with Fukutin to use CDP-ribitol 
synthesized by Isoprenoid Synthase Domain-Containing (ISPD) protein to form a tandem ribitol-
5-phosphate (Gerin et al., 2016; Kanagawa et al., 2016) that links xylose with N-
acetylgalactosamine (Taniguchi-Ikeda et al., 2016). This process is necessary for DG 
glycosylation. Patients with FKRP-associated dystroglycanopathy present with phenotypic 
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variability; however, muscle weakness and elevated serum creatine kinase are consistently 
present (Johnson et al., 2018). Depending on the molecular basis of the FKRP mutation, 
individuals with this condition may develop limb-girdle muscular dystrophy 2I (LGMD2I) or 
congenital muscular dystrophy with or without eye and brain involvement (Stensland et al., 
2011; Van Reeuwijk et al., 2010). There is some genotype-phenotype correlation in patients with 
C-terminal FKRP mutations tending to be more severe (Beltran-Valero de Bernabé et al., 2004; 
de Bernabé et al., 2003; Stensland et al., 2011; Van Reeuwijk et al., 2010). However, there is 
remarkable phenotypic variation among individuals with the same mutation (Stensland et al., 
2011). For example, a study of 25 patients homozygous for c826C/A found significant variation in 
muscle pathology, and levels of glycosylated DG (Stensland et al., 2011). Neither the 
histopathological alterations nor levels of DG glycosylation correlated with age of onset or 
walking function. Interestingly, whereas one set of siblings presented with similar clinical and 
histopathological features, a second set of siblings had dramatic variation in the age of onset (12 
vs 27 years old) (Stensland et al., 2011). These data suggest that there are modifying factors - 
environmental and/or genetic - that affect progression of FKRP-associated dystroglycanopathy. 
These data also suggest that it is imperative to study features other than muscle pathology 
and/or levels of DG glycosylation. Mouse (Ackroyd et al., 2009) and zebrafish models of FKRP 
deficiency have been used to study mechanisms associated with FKRP-associated 
dystroglycanopathy. Zebrafish models of FKRP-associated dystroglycanopathy include 
morpholino (MO) models (Kawahara et al., 2010; Thornhill et al., 2008) and a more recently 
generated fkrp mutant (Serafini et al., 2018). These studies indicate that the fkrp morphants 
phenocopy the fkrp mutant, fkrp deficiency results in impaired muscle development and 
wasting, and that laminin deposition at the MTJ is disrupted in Fkrp-deficient zebrafish. 
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Laminin is a major component of the basement membrane that surrounds muscle. 
Laminin is a heterotrimeric protein with an alpha, beta, and gamma chain. Adhesion of muscle 
fibers to laminin is necessary for muscle development and homeostasis (Bajanca et al., 2006; 
Gupta et al., 2012; Hall et al., 2007; Smith et al., 2017; Snow et al., 2008b; Yurchenco et al., 
2018). The principle laminin isoform in mature vertebrate skeletal muscle is laminin-211 (alpha2 
beta1 gamma1). Mutations in the human laminin alpha2 gene result in MDC1A, a common 
congenital muscular dystrophy (Helbling-Leclerc et al., 1995). A different laminin isoform, 
laminin-111, is the major isoform expressed during muscle development and laminin-111 is 
required for muscle development in mouse and zebrafish (Bajanca et al., 2006; Snow et al., 
2008b). Laminin-111 can partially compensate for laminin-211. Overexpression of laminin 
alpha1 slows the progression of dystrophy in laminin alpha2 mutant mice (Gawlik et al., 2004; 
Rooney et al., 2012). Injection of laminin-111 protein directly into muscle of mdx mice modeling 
Duchenne muscular dystrophy (DMD) improves muscle structure and function (Rooney et al., 
2009). These data indicate that understanding mechanisms that mediate laminin-111 expression 
and polymerization during muscle development could provide information for future 
therapeutic development. We identified a novel pathway required for laminin-111 organization 
at the zebrafish MTJ during muscle development. We found that Nicotinamide Riboside Kinase 
2b (previously called muscle Integrin binding protein (Li et al., 1999; Li et al., 2003)) is necessary 
for normal laminin-111 organization (Goody et al., 2010). Yeast and human Nrk2s function in an 
alternative salvage pathway that generates Nicotinamide Adenine Dinucleotide (NAD+) 
(Bieganowski and Brenner, 2004; Tempel et al., 2007). Exogenous NAD+ rescues MTJ 
morphogenesis in Nrk2b-deficient zebrafish, indicating that zebrafish Nrk2b also functions to 
generate NAD+ (Goody et al., 2010). Given that NAD+ biosynthesis is necessary for normal 
laminin-111 organization during muscle development, we asked whether exogenous NAD+ 
26 
 
would be sufficient to improve muscle structure and function in zebrafish modeling muscular 
dystrophies. We showed that NAD+ supplementation increases laminin organization and reduces 
muscle degeneration in zebrafish deficient for either of the laminin-211 receptors (DG or Integrin 
alpha7 (Itga7)) (Goody et al., 2012). As vitamin B3 is a precursor for NAD+, we asked whether 
vitamin supplementation would increase NAD+ and improve muscle structure and function in 
DG-deficient zebrafish. Indeed, we found that supplementation with EmergenC packets that 
contain B vitamins (chosen because they are water soluble) improves muscle structure and 
motility in DG-deficient zebrafish. 
  The two major transmembrane receptors that anchor muscle cells to laminin in their 
ECM are DG (described above) (Ervasti and Campbell, 1993; Gee et al., 1994) and Integrin alpha7 
(Itga7) (Cohn et al., 1999; Song et al., 1993). Itga7 is also required for muscle homeostasis: 
mutations in Itga7 lead to congenital muscular dystrophy with Itga7 deficiency (Hayashi et al., 
1998). These two cell adhesion complexes display some degree of functional redundancy in both 
zebrafish and mouse models. Pharmacologically increasing levels of Itga7 compensates for the 
loss of Dystrophin in a mouse model of DMD (Sarathy et al., 2017; Van Ry et al., 2015). Given 
that NAD+ is sufficient to improve muscle structure in zebrafish deficient for either laminin 
receptor complex (DG or Itga7), we hypothesized that NAD+ increases laminin organization by 
increasing clustering of the remaining receptor (Goody et al., 2012). Our model is that in the 
absence of Itga7, NAD+ increases DG clustering, thus improving muscle-ECM adhesion. Similarly, 
we hypothesize that in the absence of DG, NAD+ increases Itga7 clustering, thus improving 
muscle-ECM adhesion. This model leads to the question of whether, if DG is present but 
hypoglycosylated, NAD+ would be sufficient to improve muscle structure in a zebrafish 
secondary dystroglycanopathy model. Our previous data showed beneficial effects of NAD+ 
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when administered prior to muscle development (Goody et al., 2012). Whether NAD+ is 
beneficial after initial muscle development in this context has not yet been determined.  
  Paxillin is an Integrin-associated adaptor protein that concentrates at the MTJ during 
muscle development (Crawford et al., 2003). Paxillin is an essential signaling nexus that 
regulates cell adhesion, morphology, and migration (Deakin and Turner, 2008). Paxillin 
participates in the Nrk2b-laminin pathway. Nrk2b is cell-autonomously required for subcellular 
concentration of Paxillin at the MTJ; and Paxillin overexpression rescues muscle development 
Nrk2b-deficient zebrafish (Goody et al., 2010). DG is required for normal Paxillin concentration 
at the MTJ: DG-deficient zebrafish show reduced concentration of Paxillin at the MTJ. Addition 
of NAD+ improves Paxillin concentration at the MTJ and Paxillin overexpression reduces muscle 
degeneration in DG-deficient zebrafish (Goody et al., 2012). In contrast, Paxillin overexpression 
does not rescue zebrafish deficient for Itga7 (Goody et al., 2012). These data suggest that 
Paxillin functions downstream of NAD+ to improve muscle resilience in DG-deficient zebrafish. 
However, whether Paxillin concentration at the MTJ is disrupted in zebrafish models of 
secondary dystroglycanopathy and whether Paxillin overexpression ameliorates muscle 
degeneration in zebrafish models of secondary dystroglycanopathy have not been investigated.  
  We used the fkrp morphant model of FKRP-associated dystroglycanopathy (Kawahara et 
al., 2010; Thornhill et al., 2008) to address unanswered questions regarding NAD+ regulation of 
the ECM in a secondary dystroglycanopathy. In addition, given the data indicating that there is 
not a strict correlation between DG glycosylation levels and phenotype, we investigated 
neuromuscular junction development in fkrp morphants. We found that supplementing fkrp 
morphants with NAD+ at gastrulation improves laminin polymerization at the MTJ, muscle 
structure, and muscle function. Despite the fact that Paxillin localization is disrupted in fkrp 
morphants, Paxillin overexpression failed to rescue any of these phenotypes. Early NMJ 
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development was disrupted in fkrp morphants and improved with NAD+. To our knowledge, this 
is the first report of initial NMJ development being disrupted in an animal model of secondary 
dystroglycanopathies. As initial NMJ development has not been investigated in an animal model 
of DG deficiency, we analyzed early NMJ development in dag1 morphants. We found that NMJ 
development is disrupted in dag1 morphants, although to a lesser extent than fkrp morphants. 
In contrast to fkrp morphants, NAD+ supplementation did not improve NMJ development in 
dag1 morphants. Finally, we show that muscle-specific overexpression of fkrp improved MTJ 
morphology but was not sufficient to improve muscle structure or function. Taken together, 
these data indicate that, at least in the zebrafish, FKRP-associated dystroglycanopathy does not 
phenocopy DG-deficiency. Furthermore, these data show that Fkrp is required for normal NMJ 
development and is required in tissues other than muscle. 
2.2. Results  
2.2.1. NAD+ supplementation prior to muscle development improves muscle and MTJ 
structure  
Injection of previously published fkrp MOs recapitulated the previously described 
phenotype of fkrp morphants (Kawahara et al., 2010; Thornhill et al., 2008) and the recently 
described fkrp mutant (Serafini et al., 2018). In agreement with previous findings, multiple 
aspects of muscle development are disrupted in fkrp morphants: MTJs are significantly wider 
than in control embryos (Fig. 2.1M), muscle fibers are disorganized (Fig. 2.1L), and muscle 
degeneration is observed (Fig. 2.1H, N). Muscle fiber adhesion to the MTJ and ECM organization 
at the MTJ are disrupted in fkrp morphants (Kawahara et al., 2010; Lin et al., 2011; Thornhill et 
al., 2008). We also found that laminin (Fig. 2.1A-B, J) is reduced in fkrp morphants compared to 
controls and that beta-DG is concentrated at the MTJ, although sometimes slightly reduced (Fig. 
2.1D-E, K). We next asked whether muscle function was disrupted by quantifying the number of  
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Figure 2.1. NAD+ or EmergenC supplementation at gastrulation improves muscle structure and 
function in fkrp morphants. (A-C) Anterior left, dorsal top, side-mounted embryos at 26 hpf 
stained for laminin-111 (purple) and actin (phalloidin, green). (A, A1) Control embryo. Laminin is 
concentrated at the MTJ. (B, B1) fkrp morphant. Although laminin is present at the MTJ (white 
arrow), it is also present within the myotome (white arrowhead). (C, C1) fkrp morphant treated 
with NAD+ at 6 hpf. Laminin is concentrated at the MTJ (white arrow) as in control embryos. (D-
F1) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for beta-DG (red) and f-
actin (phalloidin, green). (D, D1) Control embryo. (E, E1) fkrp morphant. Beta-DG staining 
appears weaker at the MTJ (white arrowhead). (F, F1) fkrp morphant treated with EmergenC at 
6 hpf. Beta-DG staining appears stronger at the MTJ (white arrow). (G-I) Anterior left, dorsal top, 
side-mounted embryos at 72 hpf stained for f-actin (phalloidin, gray). (G) Control embryo. (H) 
fkrp morphant. White arrowheads indicate single detached fibers. (I) fkrp morphant treated 
with EmergenC at 6 hpf. Note the improved muscle fiber structure. (J) Relative staining intensity 
of laminin-111 at the MTJ in 26 hpf embryos, based on no staining/localization (none, white), 
weak staining/localization (weak, light gray), and strong staining/localization (strong, dark gray) 
(images were blinded prior to analysis, see methods). Controls (n=23 embryos) have greater 
laminin intensity staining than fkrp morphants (n=32 embryos). NAD+ (n=10 embryos) and 
EmergenC (n=30 embryos) supplementation improve laminin-111 concentration at the MTJ in 
fkrp morphants. (K) Relative staining intensity of beta-DG at the MTJ in 72 hpf embryos, based 
on weak staining (weak, light gray) and strong staining (strong, dark gray). Although fkrp 
morphants have more embryos with weaker beta-DG staining at the MTJ (n=7 embryos), there is 
no significant difference in beta-DG at the MTJ between untreated morphants, morphants 
treated with NAD+ (n=7 embryos), EmergenC (n=7 embryos), or control morphants (n=5 
embryos). (L) Quantification of muscle organization at 72 hpf. The anisotropy factor in embryos 
injected with fkrp MOs (n=96 half-myotomes) is reduced compared to uninjected controls (n=16 
half-myotomes), and NAD+ (n=40 half-myotomes) significantly increases the anisotropy factor in 
fkrp morphants. (M) Quantification of MTJ angles at 72 hpf. Injection of fkrp MOs (n=343 MTJs) 
significantly increases MTJ angles compared to uninjected controls (n=98 MTJs). Either NAD+ 
(n=105 MTJs) or EmergenC (n=158 MTJs) treatment significantly reduces MTJ angles compared 
to untreated morphants. (N) Untreated fkrp morphants (n=54 embryos) have a significantly 
higher percent of myotomes per embryo with fiber detachments than controls (n=40 embryos) 
at 72 hpf. NAD+ (n=31 embryos) supplementation significantly reduces the percent of 
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myotomes with dystrophy per embryo. (O) Injection of fkrp MOs (n=184 embryos) significantly 
increases the number of touches required to induce an escape response compared to 
uninjected controls (n=185 embryos). NAD+ (n=84 embryos) or EmergenC (n=111 embryos) 
treatment significantly reduces the number of touches to invoke an escape response. Scalebars 
are 50 micrometers. *p<0.05, **p<0.01, ***p<0.001, ns non-significant. 
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touches required to induce an escape response. We found that fkrp morphants have reduced 
muscle function in that they require significantly more touches to induce an escape response 
(Fig. 2.1O). These data indicate that fkrp is necessary for normal muscle development and 
function.  
We previously showed that either NAD+ or EmergenC supplementation at gastrulation is 
sufficient to improve ECM organization, reduce muscle degeneration, and improve motility in 
dag1 morphants (Goody et al., 2012). We hypothesized that NAD+/EmergenC increased laminin 
organization by potentiating clustering of the other major laminin receptors in muscles, 
Integrins alpha6/beta1 and alpha7/beta1. We asked if NAD+/EmergenC is sufficient to improve 
laminin organization in the context of impaired DG glycosylation because hypoglycosylated DG 
could hinder increased laminin organization. We found that NAD+ or EmergenC 
supplementation at gastrulation increased the concentration of laminin at the MTJ (Fig. 2.1C, J), 
decreased MTJ angles (Fig. 2.1M), decreased muscle degeneration (Fig. 2.1N), improved muscle 
fiber organization (Fig. 2.1L), and significantly reduced the touches required to evoke an escape 
response (Fig. 2.1O). These data indicate that NAD+ or EmergenC supplementation during 
gastrulation is sufficient to improve muscle development and function in Fkrp-deficient 
zebrafish. 
2.2.2. NAD+/EmergenC are not sufficient to improve vascularization, midbrain-hindbrain 
development, or the increased unfolded protein response in fkrp morphants 
Fkrp is required for normal zebrafish vascularization: fkrp morphants and the recently 
described fkrp mutant exhibit shorter intersegmental vessel (ISV) lengths compared to wild-type 
embryos (Serafini et al., 2018; Wood et al., 2011). Fli1:EGFP transgenics injected with fkrp MOs 
exhibited shorter ISV lengths (including truncated vessels) than uninjected controls (Fig. 2.2E-F,  
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Figure 2.2. NAD+ and EmergenC supplementation at gastrulation do not significantly improve 
the UPR or vascularization in fkrp morphants. (A-C1) Anterior left, dorsal top, side-mounted 3 
dpf (72 hpf) embryos expressing Tg(ef1α:xbp1δ-GFP). Fluorescence intensity was kept constant 
within an experiment (see methods). Numbered panels are merged with the brightfield channel. 
(A-A1) Control embryo. Note low relative expression of Xbp1 compared to morphants. (B-B1) 
fkrp morphant. (C-C1) fkrp morphant treated with EmergenC at gastrulation. Note that 
fluorescence intensity is similar to that of untreated morphant. (D) Quantification of Xbp1 
fluorescence intensity normalized to control fluorescence intensity for all groups imaged. 
Fluorescence intensity is significantly increased in morphants. There is no significant difference 
in fluorescence intensity between untreated morphants (n=15 embryos) and morphants 
receiving EmergenC (n=21 embryos). (E-G) Anterior left, dorsal top, side-mounted 2 dpf  
embryos expressing Tg(fli1:EGFP) focused on the ISVs. (E) Control embryo. (F) fkrp morphant 
embryo. Note that some ISVs are truncated (white arrowhead). (G) fkrp morphant embryo 
treated with NAD+ at gastrulation. Truncated ISVs are still present in NAD+ treated morphants 
(white arrowhead). (H) Quantification of ISV length. ISV length is reduced in fkrp morphants 
(n=201 vessels) compared with uninjected controls (n=84 vessels). NAD+ supplementation 
(n=166 vessels) does not rescue ISV length in fkrp morphants. Scalebars are 50 micrometers. 
*p<0.05, **p<0.01, ***p<0.001, ns non-significant. 
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Figure 2.2. 
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H). NAD+ supplementation had no significant effect on ISV length in fkrp morphants (Fig. 2.2G-
H). We also analyzed ISV length when normalized to the width of the embryos because muscle 
development is disrupted in fkrp morphants. The same result was observed with normalized 
data (not shown). These data suggest that: (1) NAD+ supplementation is not sufficient to 
improve vascularization in fkrp morphants, and (2) the vascularization defects observed in fkrp 
morphants are likely a consequence of fkrp knockdown and not aberrant muscle development 
and/or homeostasis. 
Zebrafish deficient for Fkrp exhibit abnormal midbrain-hindbrain boundary formation 
that has been likened to cobblestone lissencephaly (Thornhill et al., 2008). We also observed 
abnormal midbrain-hindbrain boundary formation in fkrp morphants at 26 hpf (n = 8 embryos) 
compared with uninjected controls. NAD+ was not sufficient to rescue midbrain-hindbrain 
boundary formation (n = 8 embryos, data not shown). Zebrafish models of FKRP-associated 
dystroglycanopathy are also associated with endoplasmic reticulum (ER) stress and activation of 
the unfolded protein response (UPR) (Lin et al., 2011). One marker of the UPR is increased 
activation of the xbp1 transcript, which is upregulated in fkrp morphants (Lin et al., 2011) and 
the recently described fkrp mutant (Serafini et al., 2018). To determine whether EmergenC 
could improve ER stress in fkrp morphants, we injected fkrp MOs into the Tg(ef1α:xbp1δ-GFP) 
line that allows visualization of xbp1 activation (Li et al., 2015). Injection of fkrp MOs increased 
the UPR (Fig. 2.2B) compared with controls (Fig. 2.2A). However, untreated and EmergenC 
treated fkrp morphants did not significantly differ in relative fluorescence intensity (Fig. 2.2C-D). 
Taken together, these results suggest that the benefits of NAD+ supplementation may be limited 
to muscle in Fkrp-deficient zebrafish. 
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Figure 2.3. Paxillin overexpression does not improve muscle structure in fkrp morphants. (A-
B3) Anterior left, dorsal top, side-mounted embryos at 26 hpf stained for Paxillin (green) and f-
actin (purple). Paxillin concentrates at the MTJ (white arrowhead) in control embryos. There are 
some gaps in Paxillin localization in fkrp morphants (B2, white arrow) and Paxillin accumulates at 
the muscle pioneers (B2, white asterisk). (C-E2) Anterior left, dorsal top, side-mounted embryos 
at 72 hpf stained for f-actin (phalloidin, gray) in lettered and even numbered panels and 
expressing Paxillin-EGFP (green) in numbered panels. (C-C2) A fkrp morphant with disorganized 
muscle fibers. (D-D2) Control Tg(hsp70l:pxna-EGFP) embryo expressing Paxillin which 
concentrates at the MTJ (white arrowhead). (E-E2) Tg(hsp70l:pxna-EGFP) fkrp morphant. (F) MTJ 
angle quantification. Fkrp morphants with (n=241 MTJs) and without (n=170 MTJs) Paxillin-EGFP 
expression have a significant increase in average MTJ angle width compared with uninjected 
controls (n=189, 191 MTJs). Paxillin overexpression in fkrp morphants significantly increases MTJ 
angles compared to morphants that do not overexpress Paxillin. (G) Fiber degeneration 
quantification. Fkrp morphants with (n=55 embryos) and without (n=60 embryos) Paxillin-EGFP 
expression have a significant increase in the percent of myotomes with degeneration per 
embryo compared to uninjected controls (n=57, 54 embryos). Although there is a trend, Paxillin 
overexpressing morphants do not have a significant reduction in dystrophy compared to control 
fkrp morphants. (H) Escape response quantification. Fkrp morphants with (n=88 embryos) and 
without (n=70 embryos) Paxillin-EGFP expression require significantly more touches to induce 
an escape response compared with uninjected controls (n=66, 80 embryos). Fkrp morphants 
overexpressing Paxillin do not exhibit a significant improvement in escape response compared 
with fkrp morphants that do not overexpress Paxillin. Scalebars are 50 micrometers. *p<0.05, 
**p<0.01, ***p<0.001, ns non-significant. 
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2.2.3. Paxillin overexpression does not significantly reduce muscle degeneration 
Paxillin is an Integrin-associated protein that is required for cell adhesion to the ECM 
(Turner et al., 1990). Paxillin concentrates at MTJs in wild-type muscle ((Crawford et al., 2003), 
Fig. 2.3). Paxillin plays a role in the Nrk2b-NAD+-laminin cell adhesion pathway. Paxillin 
concentration at the MTJ is disrupted in nrk2b morphants and rescued with NAD+ (Goody et al., 
2010). Paxillin overexpression rescues nrk2b morphants (Goody et al., 2010). Similarly, 
concentration of Paxillin at the MTJ is disrupted in dag1 morphants and is improved with NAD+. 
Paxillin overexpression improves muscle structure in dag1 morphants (Goody et al., 2012). It is 
not known if either Paxillin concentration at the MTJ is disrupted in animal models of secondary 
dystroglycanopathy or if Paxillin overexpression improves muscle structure in these models. We 
found that Paxillin concentration at the MTJ was disrupted in 26 hpf fkrp morphants (Fig. 2.3B) 
compared with controls (Fig. 2.3A). Paxillin does concentrate at the center of the MTJ adjacent 
to muscle pioneers that are slow-twitch fibers (Fig. 2.3B at the crux of the v-shaped MTJ, this 
was observed in 14/16 fkrp morphants). However, Paxillin concentration at the MTJ adjacent to 
fast-twitch muscle is disrupted (Fig. 2.3B2, arrow). These data suggest that Fkrp is required for 
normal development of the MTJ adjacent to fast-twitch muscle. Overexpression of Paxillin was 
sufficient for Paxillin to concentrate at the fast-muscle MTJ in fkrp morphants (Fig. 2.3E1 
arrowhead). However, in contrast to what we previously observed in dag1 morphants (Goody et 
al., 2012), Paxillin overexpression did not reduce muscle degeneration or improve the escape 
response in fkrp morphants (Fig. 2.3G-H). Paxillin overexpression actually increased MTJ angles 
(Fig. 2.3F). These data indicate that, in contrast to dag1 morphants, Paxillin overexpression is 
not sufficient to improve muscle structure in fkrp morphants. 
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Figure 2.4. Later NAD+ supplementation improves MTJ structure, but NAD+ and EmergenC are 
required prior to initial muscle development to improve motility, fiber resilience, and fiber 
organization. (A-D) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for f-actin 
(phalloidin, gray). (A) Control embryo. (B) fkrp morphant. (C) fkrp morphant treated with NAD+ 
at 24 hpf. (D) fkrp morphant treated with EmergenC at 24 hpf. White arrowheads indicate single 
fiber detachments. (E) Fiber organization quantification. The anisotropy factor in embryos 
injected with fkrp MOs (n=104 half-myotomes) is reduced compared to controls (n=48 half-
myotomes) and not improved with NAD+ supplementation at 24 hpf (n=96 half-myotomes). (F) 
MTJ angle quantification. Fkrp morphants treated with NAD+ (n=381 MTJs) or EmergenC (n=318 
MTJs) at 24 hpf have significantly decreased MTJ angles compared to untreated morphants 
(n=651 MTJs). (G) Fiber detachment quantification. Although there is a trend towards reduced 
muscle degeneration, fkrp morphants receiving NAD+ (n=55 embryos) or EmergenC (n=41 
embryos) at 24 hpf do not have a significant reduction in the percent of myotomes with 
dystrophy compared to untreated morphants (n=98 embryos). (H) Escape response 
quantification. The number of touches required to induce an escape response is elevated in 
embryos injected with fkrp MOs (n=128 embryos) compared to controls (n=114 embryos). 
Morphants treated with NAD+ at 24 hpf (n=81 embryos) have a worsened escape response 
compared to untreated morphants. Morphants treated with EmergenC at 24 hpf (n=52 
embryos) do not exhibit a significant change in escape response compared to untreated 
morphants, but significantly differ from NAD+ treated morphants. Scalebars are 50 
micrometers. *p<0.05, **p<0.01, ***p<0.001, ns non-significant. 
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2.2.4. NAD+ supplementation after initial muscle development improves MTJs, but not muscle 
structure 
NAD+/EmergenC supplementation prior to muscle development is sufficient to improve 
muscle structure and function in dag1 (Goody et al., 2012) and fkrp morphant embryos (Fig. 
2.1). It is not known whether NAD+ or EmergenC can improve muscle structure and function 
after initial muscle development. We supplemented fkrp morphants with NAD+ or EmergenC at 
24 hpf (after initial muscle development). Both NAD+ and EmergenC supplementation 
significantly improved MTJ angles (Fig. 2.4F). In contrast, neither NAD+ nor EmergenC 
supplementation at 24 hpf was sufficient to improve muscle fiber organization, reduce muscle 
degeneration, or improve the escape response (Fig. 2.4A-D, E, G, H). Thus, NAD+/EmergenC 
supplementation after initial muscle development is not sufficient to ameliorate muscle 
degeneration and improve muscle function in Fkrp-deficient zebrafish embryos. 
2.2.5. NMJ development is disrupted and partially improved with NAD+ supplementation in 
fkrp morphants 
The DGC is necessary for NMJ maturation after birth in mouse (Herbst et al., 2009; 
Jayasinha et al., 2003; Levedakou et al., 2005). DG glycosylation is also necessary for normal 
NMJ formation during muscle regeneration (Goddeeris et al., 2013). It is generally thought that 
DG is not required for NMJ development but is required for NMJ maturation/stabilization/ 
regeneration (Gumerson et al., 2013). We asked whether initial NMJ development is disrupted 
in secondary dystroglycanopathies. We analyzed NMJ structure at 72 hpf by staining for SV2 and 
postsynaptic AChRs (alpha-bungarotoxin). We focused on analysis of innervation of fast-twitch 
fibers (distributed innervation, see skeletons Fig. 2.5). There is an extensive network of 
distributed NMJs in 72 hpf control embryos (Fig. 2.5A). This network is qualitatively disrupted in 
fkrp morphants where there appeared to be shorter chains of NMJs (Fig. 2.5B). Supplementation  
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Figure 2.5. Fkrp morphants exhibit NMJ defects and NAD+ and EmergenC treatment prior to 
muscle development improves NMJ development. (A-D4) Anterior left, dorsal top, side-
mounted embryos at 72 hpf with labeled AChR and SV2. (Lettered panels) Merged channels of 
AChR and SV2. (1) Skeletonized images. (2) Magnification of SV2 channel. (3) Magnification of 
AChR channel. (4) Magnification of skeleton channel. (A-A4) Control embryo. (B-B4) fkrp 
morphant embryo exhibiting reduced distributed innervation within the myotome. (C-C4) fkrp 
morphant embryo treated with NAD+ at 6 hpf shows increased NMJs. (D-D4) fkrp morphant 
embryo treated with EmergenC at 6 hpf also shows increased NMJs. (E) Length of skeletons. 
Skeleton length is reduced in fkrp morphants (n=153 half-myotomes) compared to controls 
(n=144 half-myotomes), but significantly increased in fkrp morphants receiving NAD+ (n=183 
half-myotomes) or EmergenC (n=127 half-myotomes) at 6 hpf. (F) Degree of branching within 
the myotome in control embryos (n=141 half-myotomes), fkrp morphants (n=147 half-
myotomes), and fkrp morphants receiving NAD+ (n=179 half-myotomes) or EmergenC (n=126 
half-myotomes) at 6 hpf. Scalebars are 50 micrometers. *p<0.05, ns non-significant. 
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of NAD+ or EmergenC improved NMJ length, although NMJs were not fully restored (Fig. 2.5C-
D). In order to quantify innervation, we developed a semi-automated technique in MATLAB to 
skeletonize NMJs (see Chapter 5, Section 5.10.8). This analysis showed that although branching 
frequency was normal, skeleton length was reduced in fkrp morphants (Fig. 2.5E, F). NAD+ or 
EmergenC supplementation at 6 hpf slightly, but significantly, improved skeleton length in fkrp 
morphants (Fig. 5E). These results suggest that Fkrp is necessary for innervation, but not 
branching.  
As mentioned above, DG contributes to NMJ maturation and stabilization (Gumerson et 
al., 2013). Given the above data showing that initial NMJ development is disrupted in fkrp 
morphants, we asked whether DG is also required for NMJ development. We found that 
skeleton length was slightly, but significantly, reduced in dag1 morphants (Fig. 2.6B) compared 
to controls (Fig. 2.6A). However, NAD+ supplementation at gastrulation did not significantly 
increase skeleton length in dag1 morphants despite rescuing other aspects of the phenotype 
(Fig. 2.6C-D, F). This result contrasts with what we observed in fkrp morphants supplemented 
with NAD+. Thus, we compared the relative severity of NMJ skeleton length defects in fkrp 
morphants versus dag1 morphants. On average, dag1 morphant skeleton length was 83.9% of 
that of uninjected controls. In contrast, fkrp morphant skeleton length on average was 51.4% of 
that of uninjected controls (Fig. 2.6G). Thus, NMJs are more severely disrupted in fkrp 
morphants compared to dag1 morphants.  
Somewhat surprisingly, we found that NAD+ supplementation at 24 hpf actually 
significantly worsened the escape response in fkrp morphants (Fig. 2.4, p<0.05) despite the fact 
that we did not observe a significant deterioration of muscle structure. Thus, we asked how 
NAD+ supplementation at 24 hpf affected NMJ structure (Fig. 2.7). We found that the effects of 
NAD+ on NMJ structure correlated with the motility defects: NAD+ at 24 hpf resulted in 
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Figure 2.6. Skeleton length is less disrupted in dag1 morphants than in fkrp morphants and is 
not significantly improved with NAD+ supplementation. (A-C6) Anterior left, dorsal top, side-
mounted embryos at 72 hpf with labeled actin, AChRs, and SV2. (Lettered panels) Phalloidin 
stained embryos. (1) Merged channels of AChR and SV2. (2) Skeletonized images. (3) 
Magnification of phalloidin channel. (4) Magnification of SV2 channel. (5) Magnification of AChR 
channel. (6) Magnification of skeleton channel.  (A-A6) Control embryo. (B-B6) dag1 morphant 
embryo. (C-C6) dag1 morphant embryo treated with NAD+ at 6 hpf. (D) Length of skeletons per 
myotome in control embryos (n=186 half-myotomes), dag1 morphants (n=260 half-myotomes), 
and dag1 morphants receiving NAD+ (n=252 half-myotomes) at 6 hpf. Skeleton length is not 
significantly different between untreated and NAD+ treated dag1 morphants. (E) Degree of 
branching within the myotome in control embryos (n=180 half-myotomes), dag1 morphants 
(n=254 half-myotomes), and dag1 morphants receiving NAD+ (n=249 half-myotomes) at 6 hpf. 
NAD+ treatment made no significant difference. (F) MTJ angle quantification. MTJ angles are 
significantly reduced in dag1 morphants receiving NAD+ (n=98 MTJs) compared to untreated 
dag1 morphants (n=97 MTJs). (G) Bar graph of the percent skeleton length of control embryos 
per myotome. Note that the average percent skeleton length is more drastically reduced in fkrp 
morphants (51.4%, n=153 half-myotomes) than in dag1 morphants (83.9%, n=260 half-
myotomes). NAD+ supplementation increased this percentage in fkrp morphants (61.9%, n=183 
half-myotomes), but has little effect on dag1 morphants (85.0%, n=252 half-myotomes) 
Scalebars are 50 micrometers.  Error bars in (G) are standard error of the mean. *p<0.05, 
**p<0.01, ***p<0.001, ns non-significant. 
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significantly shorter skeleton lengths (Fig. 2.7E). There was no significant difference between 24 
hpf treated and untreated morphants in terms of branching frequency (Fig. 2.7F). 
2.2.6. Muscle specific FKRP expression is not sufficient to rescue fkrp morphants 
The above data indicate that Fkrp is necessary for early NMJ development and that 
disruption in NMJ morphology with 24 hpf NAD+ treatment correlates with worse motility.  
These results raise the possibility that Fkrp function is required in non-muscle tissues. We tested 
this hypothesis by expressing Fkrp in a muscle-specific manner. To confirm that constitutive Fkrp 
overexpression could rescue fkrp morphants, we injected fkrp MOs into a Tg(hsp70l:fkrp-EGFP) 
line we generated (Fig. 2.8A). Previous data suggest that overexpression of fkrp can be 
deleterious (Vannoy et al., 2017). Although we observed a slight increase in MTJ angles (Fig. 
2.8C), we did not observe any significantly adverse effects of Fkrp-EGFP on fiber degeneration or 
the escape response in control embryos (expression was induced at the 15 somite stage) (Fig. 
2.8A, D-E). Global overexpression of Fkrp-EGFP in fkrp morphants improved fiber resiliency, MTJ 
angles, and the escape response compared to control morphants (Fig. 2.8B-E). These data 
indicate that: (1) overexpression of Fkrp is not toxic under these conditions, and (2) EGFP does 
not deleteriously affect Fkrp function. We next asked whether muscle-specific expression was 
sufficient to rescue the phenotype. We generated a transgenic line expressing Fkrp-EGFP under 
control of the -503unc promoter (Berger and Currie, 2013). Muscle-specific overexpression of 
Fkrp did not affect muscle morphology in control embryos (Fig. 2.8F-F2). Muscle-specific 
overexpression of Fkrp in fkrp morphants decreased MTJ angles compared to EGFP negative 
control morphants (Fig. 2.8I). However, no other metrics of muscle structure/function were 
improved. Muscle specific overexpression neither ameliorated fiber detachment (Fig. 2.8G-H, J) 
nor reduced touches required to induce an escape response (Fig. 2.8K). These data indicate that 
expression of Fkrp in muscle is not sufficient to rescue muscle morphology or function.  
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Figure 2.7. Supplementation with NAD+ or EmergenC after muscle development does not 
improve NMJ morphology in fkrp morphants. (A-D4) Anterior left, dorsal top, side-mounted 
embryos at 72 hpf with labeled AChRs and SV2. (Lettered panels) Merged channels of AChR and 
SV2. (1) Skeletonized images. (2) Magnification of SV2 channel. (3) Magnification of AChR 
channel. (4) Magnification of skeleton channel. (A-A4) Control embryo. (B-B4) fkrp morphant 
embryo exhibiting a reduced degree of distributed innervation within the myotome. (C-C4) fkrp 
morphant embryo treated with NAD+ at 24 hpf also has reduced innervation. (D-D4) fkrp 
morphant embryo treated with EmergenC at 24 hpf has reduced NMJs. (E) Length of skeletons 
per myotome in control embryos (n=288 half-myotomes), fkrp morphants (n=303 half-
myotomes), and fkrp morphants receiving NAD+ (n=225 half-myotomes) or EmergenC (n=225 
half-myotomes) at 24 hpf. Note that skeleton length is actually significantly decreased in fkrp 
morphants receiving NAD+ at 24 hpf. (F) Degree of branching within the myotome in control 
embryos (n=283 half-myotomes), fkrp morphants (n=295 half-myotomes), and fkrp morphants 
receiving NAD+ (n=221 half-myotomes) or EmergenC (n=210 half-myotomes) at 24 hpf. 
Scalebars are 50 micrometers. *p<0.05, ns non-significant. 
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2.3. Discussion 
Dystroglycanopathies are a relatively understudied subset of muscular dystrophies. One 
aspect of dystroglycanopathies that is not well understood is how the myomatrix is impacted. 
Whether strategies that improve the myomatrix and muscle structure in a primary 
dystroglycanopathy (DG deficiency) are efficacious in secondary dystroglycanopathies are also  
not known. We previously showed that either NAD+ supplementation or overexpression of an 
Integrin-associated adaptor protein (Paxillin) are sufficient to improve muscle structure and 
function in DG-deficient zebrafish. Here we show that muscle phenotypes in a zebrafish model 
of FKRP-associated dystroglycanopathy are improved with NAD+ supplementation but not 
Paxillin overexpression. Although the mechanisms are not known, these data clearly indicate 
that primary and secondary dystroglycanopathies show some differences. Our data also suggest 
that there are differences even within secondary dystroglycanopathies. Whereas muscle-specific 
expression of Large is sufficient to rescue muscle structure and function in Large/myd mutant 
mice (Gumerson et al., 2013), we found that muscle-specific expression of fkrp is not sufficient 
to improve muscle structure/function in fkrp morphant zebrafish. Finally, our data show that 
NMJ formation is disrupted earlier in development than has previously been observed in a 
primary and secondary dystroglycanopathy model. Taken together, these data indicate that it is 
necessary to study the secondary dystroglycanopathies individually within the context of the 
group as a whole. 
2.3.1. Cell-matrix adhesion and secondary dystroglycanopathy 
  Adhesion of muscle fibers to the MTJ is necessary for muscle development and 
homeostasis. We previously identified a cell adhesion pathway that contributes to laminin 
organization at the MTJ: Nrk2b-mediated NAD+ production potentiates laminin organization at 
the MTJ during zebrafish muscle development (Goody et al., 2010). We then demonstrated that 
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Figure 2.8. Muscle-specific overexpression of Fkrp improves MTJ angles, but not motility or 
fiber resiliency. (A-B2) Anterior left, dorsal top, side-mounted embryos at 72 hpf stained for f-
actin (phalloidin, gray) and expressing Fkrp-EGFP (green). (A-A2) Control Tg(hsp70l:fkrp-EGFP) 
embryo expressing Fkrp in the fibers. (B-B2) fkrp morphant Tg(hsp70l:fkrp-EGFP) embryo 
expressing Fkrp in fibers. (C) MTJ angles of Tg(hsp70l:fkrp-EGFP) control (n=264 MTJs) and fkrp 
morphant (n=340 MTJs) embryos and AB controls and morphants (n=141, 194 MTJs) at 72 hpf. 
Constitutive expression of Fkrp improves MTJ angles in morphants. (D) Constitutive expression 
of Fkrp in morphants (n=72 embryos) significantly reduces the number of myotomes with fiber 
degeneration compared with control morphants (n=35 embryos). (E) The escape response is 
significantly reduced in fkrp morphants constitutively overexpressing Fkrp (n=82 embryos) 
compared to control morphants (n=44 embryos). (F-H2) Anterior left, dorsal top, side-mounted 
embryos at 72 hpf stained for f-actin (phalloidin, gray) and expressing Fkrp-EGFP under control 
of the muscle-specific -503unc promoter (green). (F) Control Tg(-503unc:fkrp-EGFP) embryo 
expressing Fkrp specifically in muscle fibers. G) fkrp morphant embryo on Tg(-503unc:fkrp-EGFP) 
background lacking Fkrp expression in muscle fibers. (H) fkrp morphant Tg(-503unc:fkrp-EGFP) 
embryo expressing Fkrp specifically in muscle fibers does not show improved muscle 
organization. (I) Muscle specific expression of FKRP in fkrp morphants (n=158 MTJs) significantly 
improves MTJ angles compared to control morphants (n=153 MTJs). (J) Muscle-specific 
overexpression of Fkrp (n=45 embryos) does not significantly lower the percent of myotomes 
with muscle degeneration in control fkrp morphants (n=47 embryos). (K) There is not a 
significant difference in the number of touches required to induce an escape response in fkrp 
morphants that overexpress Fkrp (n=73 embryos) in muscle versus those that do not (n=79 
embryos). Scalebars are 50 micrometers. *p<0.05, **p<0.01, ns non-significant. 
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exogenous NAD+ is sufficient to improve laminin organization, muscle structure, and muscle 
function in zebrafish deficient for either DG or Itga7 (Goody et al., 2012). DG and Itga7 are both 
transmembrane receptors for laminin. We hypothesized that NAD+ improved laminin 
organization, at least in part, by increasing clustering of the remaining receptor (DG in Itga7-
deficient embryos, and Itga7 in DG-deficient embryos). Here, we asked whether laminin  
organization would be increased if DG is present but hypoglycosylated. The rationale was that it 
is possible that the presence of hypoglycosylated DG that cannot bind laminin could inhibit the 
improvement of laminin organization with NAD+. The ribitol 5-phosphate transferase FKRP is 
necessary for proper glycosylation of DG (Gerin et al., 2016; Kanagawa et al., 2016). We asked if 
NAD+ was sufficient to improve cell-matrix adhesion in fkrp morphant zebrafish embryos. We 
found that NAD+ supplementation prior to muscle development was sufficient to improve 
laminin polymerization, muscle structure, and the escape response.  
  Organization of laminin at the MTJ is disrupted in zebrafish deficient either for DG 
(Goody et al., 2012) or Fkrp (Kawahara et al., 2010; Lin et al., 2011; Thornhill et al., 2008) (Fig. 
2.1). Laminin is required for concentration of the Integrin adaptor protein Paxillin to the MTJ 
(Goody et al., 2010). Paxillin is an intracellular protein that localizes to cell-ECM adhesion 
complexes (Deakin and Turner, 2008) and modulates ECM composition at the developing MTJ 
(Jacob et al., 2017). Previous data regarding the beneficial potential of Paxillin in the context of 
aberrant muscle development/homeostasis are contradictory. Paxillin overexpression worsens 
muscle damage in ethanol-treated zebrafish (Coffey et al., 2018). However, Paxillin 
overexpression is sufficient to improve MTJ morphology in Nrk2b-deficient zebrafish (Goody et 
al., 2010). Paxillin overexpression also improves laminin organization and reduces muscle 
degeneration in dag1 morphant zebrafish (Goody et al., 2012). We hypothesized that Paxillin 
overexpression would improve muscle structure and function in fkrp morphants where DG is 
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present but not properly glycosylated. Interestingly, we found that Paxillin expression trended 
towards reducing degeneration and improving the escape response, but the effects were not 
significant (Fig. 2.3). This result suggests the hypothesis that, in contrast to the situation where 
DG is absent, the presence of hypoglycosylated DG in the membrane prevents Paxillin-mediated 
stabilization of muscle fibers.  
2.3.2. Benefits of NAD+ supplementation may be restricted to the neuromusculoskeletal 
system 
  Both fkrp morphants and mutants have an increased UPR. Xpb1, a marker of the UPR, is 
upregulated in both fkrp morphants and fkrp mutants (Lin et al., 2011; Serafini et al., 2018). 
Expression of bip, a marker of the UPR, is upregulated in fkrp morphants at 28 hpf, especially in 
the neural floor plate and the hatching gland (Lin et al., 2011). However, glytl1b (large2) 
morphants with hypoglycosylated DG, dag1 morphants, and sly/lam1c mutants do not exhibit 
bip upregulation (Lin et al., 2011), suggesting that activation of the UPR may result directly from 
loss of Fkrp. We asked if EmergenC supplementation was sufficient to reduce the UPR in fkrp 
morphants. We found that 3 dpf Tg(ef1α:xbp1δ-GFP) embryos injected with fkrp MOs have 
increased xbp1-GFP fluorescence compared to control embryos. EmergenC supplementation at 
gastrulation was not sufficient to reduce xbp1-GFP fluorescence. Taken together, these data 
suggest that activation of the UPR occurs independently of muscle-cell matrix adhesion and DG 
glycosylation and is likely a direct consequence of Fkrp knockdown. 
  Fkrp morphants and fkrp mutants also exhibit aberrant vascular development, including 
reduced ISV lengths (Serafini et al., 2018; Wood et al., 2011). One study suggests that impaired 
vascularization directly results from loss of Fkrp and that muscle phenotypes and vascular 
phenotypes are independent of one another (Wood et al., 2011). Here, we demonstrate that 
NAD+ supplementation at gastrulation is not sufficient to rescue truncated ISVs in fkrp 
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morphants. Given that NAD+ improves muscle structure and function in fkrp morphants, our 
data suggest that vascular phenotypes observed in fkrp morphants are not dependent on 
muscle phenotypes. This supports the previous hypothesis that abnormal vascular development 
in zebrafish models of FKRP-associated dystroglycanopathy is a direct result of loss of Fkrp. 
2.3.3. Timing of NAD+ intervention is critical  
Gene therapy (Qiao et al., 2014; Thomas et al., 2016; Tucker et al., 2018; Vannoy et al., 
2017), estrogen receptor modulators (Wu et al., 2018), and exogenous ribitol supplementation 
(Cataldi et al., 2018) improve muscle structure in FKRP-associated dystroglycanopathy models. 
The efficacy of adenoviral gene therapy and ribitol supplementation decreases if administered 
later in the mouse’s lifespan (Cataldi et al., 2018; Vannoy et al., 2017), suggesting that early 
intervention is most beneficial. Our data regarding the timing of NAD+ and EmergenC 
supplementation in fkrp morphants are consistent with the data mentioned above. We found 
that NAD+ (or EmergenC) supplementation prior to muscle development increased laminin 
organization, reduced muscle degeneration, improved muscle function, and improved NMJ 
structure (Fig. 2.1). In contrast, NAD+ (or EmergenC) supplementation after initial muscle 
development only improved MTJs and not muscle structure/function (Fig. 2.4).  
Our data do not resolve why MTJ morphology is improved with late NAD+ 
supplementation or muscle-specific overexpression of Fkrp. Improved MTJ morphology does not 
always correlate with fiber degeneration. Itga7 morphants exhibit muscle fiber detachment but 
have normal MTJ morphology, and NAD+ supplementation improves MTJ angles, but not fiber 
degeneration in dag1/itga7 double morphants (Goody et al., 2012). Movement is not necessary 
for MTJ chevron formation in zebrafish embryos (Rost et al., 2014). We show that motility is not 
improved in fkrp morphants receiving NAD+ or EmergenC after initial muscle development, 
further suggesting that improved MTJ morphology does not always correlate with mobility. 
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While this manuscript was in preparation, it was shown that administration of pentetic 
acid at 48 hpf improved muscle and pericardiac phenotypes in a fkrp zebrafish model of LGMD2I 
(Serafini et al., 2018). Pentetic acid is a chelating agent that binds Ca2+ and Mg2+. The 
mechanism by which this improves muscle phenotypes is currently unknown. However, 
abnormal Ca2+ levels have been implicated in DMD and inducing an influx of Ca2+ is sufficient 
to induce dystrophy (Millay et al., 2009). Together, these data suggest that different therapeutic 
avenues have different time windows of efficacy in multiple animal models.  
2.3.4. Dag1 and fkrp are required for proper NMJ development  
  NMJ development requires orchestrated interactions between muscle cells and motor 
neurons. The DGC is a major component of NMJs. Thus, it is not surprising that NMJ morphology 
is disrupted in multiple dystroglycanopathies. Fukutin-deficient chimeric mice have abnormal 
AChR clustering and NMJs at postnatal day 15 (Saito et al., 2007). Newborn pups homozygous 
for Large/myd mutations have altered NMJs as well (Herbst et al., 2009). These data clearly 
indicate that NMJs are abnormal after birth. What is not clear is at which point in embryonic 
development NMJ disruption occurs. Do NMJs develop normally and then degenerate or is initial 
NMJ development abnormal? Here, we provide evidence that early NMJ development is slightly 
disrupted in DG-deficient zebrafish, with NMJ chains that innervate fast-twitch muscle being 
approximately 84% of control chain length. To our knowledge, this is the earliest developmental 
stage at which NMJ disruption has been observed in a primary or secondary dystroglycanopathy. 
Interestingly, fkrp morphants exhibit more dramatic disruption of NMJ morphology, with NMJ 
chains about half of control chain length. We do not know the mechanisms underlying the more 
severe disruption in NMJ development in fkrp versus dag1 morphants. One possibility is that 
hypoglycosylated dag1 acts as a “dominant negative” and thus disrupts NMJ development more 
than when dag1 is not present. Additionally, there are many glycosylated proteins at the MTJ, 
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such as Lrp2, Musk, and Agrin. Thus, the more severe disruption in fkrp morphants could also 
reflect a requirement of Fkrp for glycosylation of other NMJ resident proteins. 
2.3.5. Muscle-specific overexpression of Fkrp is not sufficient to rescue fkrp morphants 
Overexpression of LARGE is sufficient to synthesize glycan-enriched alpha-DG and is 
sufficient to improve laminin binding activity in multiple dystroglycanopathy patient cell lines 
(Barresi et al., 2004). Muscle-specific expression of Large is sufficient to rescue muscle structure, 
neurotransmission, and NMJs in Large/myd mutant mice (Gumerson et al., 2013). NMJ defects 
in Large/myd mutant mice were observed after birth (Herbst et al., 2009). The above data 
suggest that, in the context of Large-associated Dystroglycanopathy, NMJ defects are secondary 
to muscle disruption. Given that we observed very early developmental disruption of NMJs, we 
couldn’t necessarily conclude that NMJ disruption in Fkrp-deficient embryos is secondary to the 
muscle phenotype. Thus, we tested whether muscle-specific expression of Fkrp would be 
sufficient to rescue neuromuscular function in fkrp morphant embryos. We first showed that 
global expression of Fkrp (under control of the heat shock promoter) is sufficient to rescue fkrp 
morphant embryos. This result indicates that the Fkrp-EGFP fusion protein is functional.  
Next, we expressed Fkrp in muscle under control of the muscle specific -503unc 
promoter (Berger and Currie, 2013). We found that muscle-specific expression of Fkrp was 
sufficient to slightly, but significantly, reduce MTJ angles. However, muscle-specific expression 
of Fkrp was not sufficient to reduce muscle degeneration or improve the escape response (Fig. 
2.8). We do not know why our results differ from the Large study. We do not believe that timing 
of expression is the key factor because muscle creatine kinase (Large study) and Unc45b (our 
study) are expressed at similar times during myotome development. In the DG glycosylation 
pathway, FKRP works in concert with Fukutin (FKTN) to synthesize a tandem ribitol phosphate 
that connects a core o-linked glycan with matriglycan, the ligand for laminin and other ECM 
57 
 
proteins (Gerin et al., 2016; Kanagawa et al., 2016). This step precedes the completion of 
matriglycan synthesis by LARGE. Roles for LARGE or FKRP in other glycosylation reactions have 
not been identified. However, the fact that muscle-specific expression of Fkrp is not sufficient to 
rescue muscle homeostasis may suggest that Fkrp is required to glycosylate proteins other than 
DG. Regardless, our data indicate that Fkrp is required outside of skeletal muscle to reduce 
muscle degeneration. In the future it will be interesting to determine in which tissues and cells 
Fkrp is required to rescue neuromuscular function in Fkrp-deficient embryos.  
2.4. Conclusion  
 The myomatrix is critical for muscle development and homeostasis and is disrupted in 
many dystroglycanopathies studied thus far (Di Costanzo et al., 2014; Lin et al., 2011; Marchese 
et al., 2016; Roscioli et al., 2012; Stevens et al., 2013). Here, we primarily focused on two 
specialized junctions within the myomatrix: the MTJ and NMJ. MTJ and NMJ development are 
disrupted in fkrp morphants. NAD+ supplementation prior to muscle development, which 
improves myomatrix organization in DG-deficient zebrafish, was sufficient to improve muscle 
homeostasis, MTJ structure, and NMJ formation in fkrp morphant zebrafish. However, NAD+ did 
not improve vascular or UPR phenotypes in fkrp morphants, and NAD+ supplementation after 
initial muscle development was not particularly efficacious. There was a slight improvement in 
MTJ structure and a reduced variation in muscle degeneration. These data are similar to 
previous studies showing that earlier intervention has improved outcomes in FKRP mutant mice 
(Cataldi et al., 2018; Vannoy et al., 2017). Interestingly, in contrast to muscle-specific expression 
of Large in Large/myd mutant mice, muscle-specific overexpression of Fkrp was not sufficient to 
improve muscle structure/function in fkrp morphants. Taken together, our data indicate that 
Fkrp plays an early and crucial role in muscle, MTJ, and NMJ development.   
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CHAPTER 3 
PHENOTYPIC VARIATION AND PLASTICITY IN A ZEBRAFISH MODEL OF  
GMPPB-ASSOCIATED DYSTROGLYCANOPATHY 
3.1. Introduction 
 Skeletal muscle is a tissue that is conserved among many organisms and is necessary for 
strength and locomotion. It is a highly plastic tissue that undergoes changes in size based on 
genetic and/or environmental cues. Skeletal muscle may grow in size (hypertrophy) in response 
to diet and exercise. However, aging (sarcopenia), cancer cachexia, a lack of exercise, and 
neuromuscular diseases such as muscular dystrophies can cause a loss of muscle mass (atrophy). 
Individuals with muscular dystrophies and similar conditions often possess remarkable variation 
in both the level of muscle atrophy and the ability to regenerate skeletal muscle, even when the 
molecular basis of their condition is similar. The mechanisms that contribute to this phenotypic 
variation among individuals with the same type of muscular dystrophy remain poorly 
understood. 
One group of muscular dystrophies where phenotypic variation is common are the 
dystroglycanopathies. These are a suite of molecularly distinct conditions that result from 
mutations in in genes responsible for glycosylating Dystroglycan (DG) (Godfrey et al., 2011; 
Inamori et al., 2012; Muntoni et al., 2011). DG is a major component of the dystrophin-
glycoprotein complex (DGC) that helps link the actin cytoskeleton of muscle fibers with laminin 
and other extracellular matrix (ECM) proteins. It contains a transmembrane beta subunit and an 
extracellular alpha subunit that binds to laminin and other ECM proteins (Muntoni et al., 2011). 
Alpha-DG must be glycosylated by a team of glycosyltransferases in order to bind to its ligands. 
Patients with dystroglycanopathies often present with either limb-girdle muscular dystrophies 
(LGMDs) or with congenital muscular dystrophies (CMDs) (Muntoni et al., 2008; Taniguchi-Ikeda 
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et al., 2016). Central nervous system defects are sometimes present in dystroglycanopathy 
patients with CMDs (Nickolls and Bönnemann, 2018); however, the role of alpha-DG 
glycosylation in the peripheral nervous system in dystroglycanopathies is less understood. 
Neuromuscular junction (NMJ) disruption has been reported in mouse models of 
dystroglycanopathy (Côté et al., 1999; Herbst et al., 2009; Levedakou et al., 2005; Saito et al., 
2007). Additionally, alpha-DG glycosylation is necessary for NMJ formation in regenerating 
skeletal muscle (Goddeeris et al., 2013). We recently found that zebrafish deficient for DG or 
Fkrp exhibit NMJ defects during the late embryonic stages (Chapter 2). These data suggest that 
DG glycosylation enzymes are essential for NMJ formation. Despite these findings, the timing 
and mechanisms behind disrupted NMJ development remain unclear.  
GMPPB-associated dystroglycanopathy is associated with phenotypes in both muscle 
and NMJs. This condition results from mutations in GDP-Mannose Pyrophosphorylase B 
(GMPPB), an enzyme that participates in DG glycosylation. GMPPB converts mannose-1-
phosphate to GDP-mannose, which is subsequently used in several glycosylation reactions such 
as C-mannosylation and N-glycosylation (Carss et al., 2013). Patients with GMPPB-associated 
dystroglycanopathy present with phenotypic variation. Similar to other dystroglycanopathies, 
individuals with GMPPB mutations develop milder, adolescent- or adult-onset limb-girdle 
muscular dystrophies or severe congenital muscular dystrophies with central nervous system 
involvement (Bharucha-Goebel et al., 2015; Cabrera-Serrano et al., 2015; Carss et al., 2013; 
Jensen et al., 2015; Oestergaard et al., 2016; Raphael et al., 2014). Although genotype-
phenotype correlations have emerged in regard to these phenotypes (Jensen et al., 2015), there 
is still phenotypic variation within individuals with the same molecular GMPPB variants, even 
within families (Bharucha-Goebel et al., 2015). For example, individuals with the common c.79 
G>C mutation associated with limb-girdle muscular dystrophy may also develop congenital 
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myasthenic syndrome (CMS) (Belaya et al., 2015; Luo et al., 2017; Rodríguez Cruz et al., 2016). 
CMS is a neuromuscular disorder characterized by poor neuromuscular transmission at the NMJ 
(Finsterer, 2019). The age of symptomatic onset in individuals with the c.79 G>C variant is highly 
variable (Bharucha-Goebel et al., 2015; Montagnese et al., 2017). Cases of epilepsy (Astrea et 
al., 2018; Raphael et al., 2014), one case of autism spectrum disorder (Astrea et al., 2018), 
pseudometabolic myopathy (Panicucci et al., 2018), and rhabdomyolysis (Cabrera-Serrano et al., 
2015) have also been reported in individuals with GMPPB mutations. These clinical studies 
suggest that the phenotypic diversity observed with these disorders may be a result of genetic 
and/or environmental factors. The above studies also suggest the importance of studying neural 
features associated with these disorders and indicate that it is critical to examine how muscle 
phenotypes develop or change over the course of one’s illness.  
Most of the research concerning GMPPB-associated dystroglycanopathy has been 
clinical and does not address the biological mechanisms underlying this disorder. Animal model 
studies regarding GMPPB are limited. Gmppb morphant zebrafish exhibit sarcolemmal damage, 
MTJ abnormalities, bent tails, and hypoglycosylated alpha-DG (Carss et al., 2013). There are 
currently no published genomic models for this disorder in mouse, zebrafish, Drosophila, or any 
other model organism. Zebrafish offer many advantages for studying neuromuscular diseases 
such as GMPPB-associated dystroglycanopathy. They are externally fertilized, possess high 
fecundity and rapid development, and are transparent for the first several days of life (reviewed 
by (Gibbs et al., 2013)). This allows for visualization of their muscle and/or nerves via 
immunofluorescence microscopy. Recently, genome editing techniques such as TALENs and 
CRISPR/Cas9 have made genomic manipulations more precise and accessible in zebrafish 
(reviewed by (Cornet et al., 2018; Liu et al., 2019; Rafferty and Quinn, 2018; Simone et al., 
2018)). Zebrafish have been especially advantageous in elucidating the cell behaviors in the 
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context of neuromuscular disorders, including muscle cell-ECM adhesion mechanisms. We 
previously found that Nrk2b-mediated NAD+ production potentiates laminin organization at the 
MTJ during zebrafish muscle development (Goody et al., 2010). We then determined that 
exogenous NAD+ is sufficient to improve laminin organization, muscle structure, and function 
two zebrafish models of dystroglycanopathy ((Goody et al., 2012), Chapter 2). However, 
whether NAD+ remains beneficial for GMPPB-associated dystroglycanopathy has not been 
investigated. 
To address questions regarding cell-ECM adhesion and neuromuscular phenotypic 
variation in GMPPB-associated dystroglycanopathy, we used CRISPR/Cas9 mutagenesis to 
engineer a gmppb mutant zebrafish line. Programmed DNA was inserted near the 3’ end of 
intron 2. RNA-seq analyses revealed the presence of multiple splice variants in gmppb mutants 
that are predicted to result in premature stop codons. We determined that gmppb mutants 
have abnormal beta-DG localization. Surprisingly, we found that NAD+ supplementation is not 
sufficient to rescue muscle and MTJ phenotypes. Additionally, gmppb mutants exhibited 
phenotypic variation, and “severe” embryos had wider MTJ angles and increased levels of 
dystrophy compared to “mild” embryos. We detected defects in early primary motoneuron 
development in gmppb mutants. Although gmppb mutants exhibited NMJ defects, these were 
not significantly different between “mild” and “severe” gmppb mutants. We subsequently found 
that gmppb mutants can be quantitatively separated into mild and severe phenotypes based on 
birefringence image analysis at 2 dpf. Longitudinal experiments revealed that a portion of 
gmppb mutants initially presenting with severe phenotypes recovered to milder phenotypes by 
7 dpf. Taken together, these results suggest that gmppb mutants exhibit a degree of phenotypic 
variability similar to that of humans and undergo phenotypic shifts throughout the first several 
days of life. 
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3.2. Results 
3.2.1. Characterization of gmppb mutants 
 In humans, the most commonly reported GMPPB mutation is single-nucleotide 
substitution associated with phenotypic variation: c.79 G>C (Bharucha-Goebel et al., 2015; 
Cabrera-Serrano et al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al., 2017; 
Oestergaard et al., 2016; Raphael et al., 2014). To answer questions regarding cell-ECM 
adhesion and phenotypic variation in the context of GMPPB-associated dystroglycanopathy, we 
used CRISPR/Cas9 mutagenesis (Gagnon et al., 2014) to engineer a zebrafish gmppb mutant. A 
preliminary RNA-seq experiment was performed on a pool of wild-type and gmppb mutants. 
This experiment revealed that programmed DNA was inserted near the junction of intron 2 and 
exon 3 of gmppb as expected (Appendix B). In addition to detecting correctly spliced gmppb 
transcripts, we detected four alternative splice variants in the gmppb mutant samples (Fig. 3.1B-
C, Appendix B). At least three of these variants are predicted to result in premature stop codons 
(Fig. 3.1A1, Appendix B). These data suggest that gmppb mutants are hypomorphic in nature. 
  The zebrafish gmppb morphant exhibits reduced body size, smaller eyes, and 
disorganized muscle fibers that cross the myotome boundaries at 48 hpf (Carss et al., 2013). We 
found that gmppb mutant embryos had abnormal tail morphology (Fig. 3.1F), as well as muscle 
fibers spanning multiple myotomes (MTJ failure) and fiber detachment (Fig. 3.1G-G2, I-I1). These 
data show that aberrant muscle phenotypes are present in this model, suggesting that gmppb 
mutants an attractive model for studying cell-matrix adhesion in the context of GMPPB-
associated dystroglycanopathy.  
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Figure 3.1. Characterization of gmppb mutant zebrafish embryos. (A) Biochemical function of 
GMPPB. Note that GMPPB synthesizes GDP-mannose from mannose-1-phosphate and this 
product is used in several glycosylation reactions. Adapted from Carss et al. (2013).  (A1) 
Predicted location of the gmppb mutation relative to two common mutations in human 
populations. Based on RNA-seq data, the gmppb mutation is predicted to introduce premature 
stop codons in the nucleotidyl transferase domain of the protein due to alternative splicing. 
Schematic adapted from Carss et al. (2013). (B-C) Proposed mechanisms of RNA splicing in wild-
type (B) and mutant (C) embryos. The insertion of the stop cassette (blue) in intron 2-3 (yellow) 
introduces alternative splice sites that generate alternative RNA transcripts. (D-E) Anterior left, 
dorsal top, side-mounted 2 dpf wild-type embryos. (D-D1) Live brightfield (D) and birefringence 
(D1) images of 2 dpf wild-type embryo. (E-E2) Wild-type embryo stained for f-actin (phalloidin, 
gray). Note normal MTJ morphology (white arrow) and lack of fiber detachment. (F-G) Anterior 
left, dorsal top, side-mounted 2 dpf gmppb mutant embryos. (F-F1) Live brightfield (F) and 
birefringence (F1) images of 2 dpf gmppb mutants. Note abnormal posterior morphology (black 
arrowhead). (G-G2) Mutant embryo stained for f-actin (phalloidin, gray). Note breaks in MTJ 
(white arrowhead) and fiber detachment (red arrowhead) that are not present in the wild-type 
embryo. (H-I1) Anterior left, dorsal top, side-mounted 3 dpf embryos stained for f-actin 
(phalloidin, gray). (H-H1) Wild-type embryo. Note lack of fiber detachments or crossings. (I-I1) 
gmppb mutant embryo. Note muscle fibers crossing the MTJ boundaries. Scalebars are 50 
micrometers.  
  
64 
 
Figure 3.1. 
65 
 
  3.2.2. NAD+ is not sufficient to improve muscle phenotypes in gmppb mutants 
  NAD+/EmergenC supplementation prior to muscle development is sufficient to improve 
muscle phenotypes in both dag1 morphant (Goody et al., 2012) and fkrp morphant zebrafish 
(Fig. 2.1). Given that exogenous NAD+ reduces muscle degeneration in both of these 
circumstances and that gmppb mutants exhibit muscle and MTJ phenotypes, we hypothesized 
that NAD+ would improve muscle phenotypes in gmppb mutant embryos. Surprisingly, NAD+ 
supplementation was not sufficient to significantly improve MTJ angles, MTJ failure, and 
dystrophy in gmppb mutant embryos (Fig. 3.2A-E). Patients with GMPPB mutations exhibit 
variability in sarcolemmal beta-DG accumulation (Bharucha-Goebel et al., 2015; Cabrera-
Serrano et al., 2015; Jensen et al., 2015; Oestergaard et al., 2016) and sometimes present with 
Western blot mobility shifts in beta-DG (Sarkozy et al., 2018). We asked if beta-DG localization 
was disrupted in gmppb mutants and found that isolated myofibers exhibited mislocalized beta-
DG and abnormal clustering of beta-DG on the edges of the fibers (Fig. 3.2G-H1) compared to 
WT embryos (Fig. 3.2F-F1). Additionally, gmppb mutant myofibers were more circular in shape 
than wild-type myofibers (Fig. 3.2J). Our results suggest that beta-DG mislocalization occurs in 
gmppb mutants. 
3.2.3. Gmppb mutants exhibit phenotypic variation in muscle 
 Humans harboring GMPPB mutations exhibit a broad range of symptoms and severities, 
even when individuals have identical genetic variants (Belaya et al., 2015; Cabrera-Serrano et al., 
2015; Luo et al., 2017). Gmppb mutant zebrafish are an ideal model to address questions 
regarding neuromuscular phenotypic variation. We imaged 72 hpf wild-type and gmppb mutant 
embryos labeled for f-actin (phalloidin) to quantify MTJ angles, MTJ failure, and dystrophy at 
this stage. We determined that compared to wild-type embryos (Fig. 3.3A), gmppb mutants 
exhibit differences overall in terms of muscle (Fig. 3.3B, C). Additionally, we observed  
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Figure 3.2. Gmppb mutants are not rescued by NAD+ supplementation and have abnormal 
beta-DG localization. (A-B1) Anterior left, dorsal top, side-mounted embryos stained for f-actin 
(phalloidin, gray). (A-A1) 72 hpf gmppb mutant. Note fiber detachment in the myotome (white 
arrowhead). (B-B1) 72 hpf gmppb mutant treated with 0.1 mM NAD+ at 6 hpf. Note the muscle 
fibers spanning multiple myotomes (yellow arrowhead). (C) MTJ angles are significantly 
increased in gmppb mutant embryos (n=107 MTJs) compared to untreated (n=49 MTJs) and 
NAD+-treated (n=58 MTJs) wild-type embryos. MTJ angles are not significantly reduced in NAD+-
treated gmppb mutants (n=84 MTJs) compared to untreated mutants. (D) There is not a 
significant difference in MTJ failure between gmppb mutants treated with NAD+ (n=19 embryos) 
and untreated gmppb mutants (n=19 embryos). (E) There is no significant difference in the 
percent of myotomes with degeneration between gmppb mutants treated with (n=19 embryos) 
and without (n=19 embryos) NAD+. (F-H1) Individual myofibers purified from 48 hpf embryos 
stained for phalloidin (lettered panels, gray) and beta-DG (numbered panels, blue). (F-F1) 
Control myofiber. Note that beta-DG localizes to the terminal edges of the myofibers (white 
arrowhead). (G-H1) Gmppb mutant myofibers. Note how beta-DG is aggregated along the 
myofibers (yellow arrowhead) and does not localize to the terminal ends. (I) There is no 
significant difference in myofiber area between control (n=16 myofibers) and gmppb mutant 
(n=38 myofibers) myofibers. (J) Myofiber shape was quantified in control (n=16 myofibers) and 
gmppb mutant myofibers (n=38 myofibers) using the filament index. This metric quantifies how 
much an object deviates from a circular shape: a lower filament index corresponds with a more 
circular shape (Snow et al., 2008b). There is a significant reduction in the filament index in 
gmppb mutants compared with controls. This suggests that gmppb mutant myofibers are more 
circular. Myofiber scalebars are 10 micrometers, other scalebars are 50 micrometers, *p<0.05, 
**p<0.01, ***p<0.001, ns non-significant. 
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phenotypic variation within gmppb mutants, with embryos appearing “mild” or “severe” (Fig. 
3.3B, C, Chapter 5, Section 5.10.2). Prior to staining our embryos, we performed a motility assay 
and found that “severe” and “mild” gmppb mutants did not have statistically significant 
differences in motility (Fig. 3.3D). We quantified MTJ angles, MTJ failure, and levels of dystrophy 
in “mild” and “severe” gmppb mutants. “Severe” mutants had significantly worse MTJ angles 
and increased levels of dystrophy compared to “mild” gmppb mutants (Fig. 3.3E, G). Although 
we observed a trend in increased MTJ failure that correlated with phenotypic severity, this trend 
was not significantly different between either class of mutant or wild-type embryos (Fig. 3.3F, 
p=0.07 for wild-type and “severe” mutants). Taken together, these data suggest gmppb mutants 
exhibit phenotypic variation in muscle. 
3.2.4. Gmppb mutants exhibit neural phenotypes 
  Neuromuscular junction (NMJ) development requires tight coordination between both 
motoneurons and muscle cells. Congenital myasthenic syndromes that affect the NMJ have 
been documented in a number of patients with GMPPB-associated dystroglycanopathy (Belaya 
et al., 2015; Luo et al., 2017; Rodríguez Cruz et al., 2016). We asked if motor axon pathfinding 
and initial NMJ development are disrupted in gmppb mutants and if “mild” and “severe” 
embryos exhibit differences in NMJ morphology. We found that CaP (ventral) primary motor 
axon development was disrupted in 24 hpf gmppb mutant embryos compared to wild-type 
embryos (Fig. 3.4A-C). A lower percentage of primary motor axons exited the spinal cord (Fig. 
3.4D) and extended past the choice point (Fig. 3.4F) in gmppb mutants compared to controls. 
However, we did not observe any significant differences in the axon length to the choice point 
(Fig. 3.4E) or the length of the axons that extend beyond the choice point (Fig. 3.4G) between 
either group. These data suggest that initial motoneuron development is disrupted in gmppb 
mutants. 
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Figure 3.3. Gmppb mutants exhibit phenotypic variation in muscle. (A-C) Anterior left, dorsal 
top, side-mounted 72 hpf embryos stained for f-actin (phalloidin, gray). (A) Control embryo. (B) 
“Mild” gmppb mutant embryo. Note subtle fiber degeneration within the myotome (yellow 
arrowhead) and wider MTJs. (C) “Severe” gmppb mutant embryo. Note abnormal myotome 
shape (white arrowhead), fiber disorganization, and wider MTJs. (D) Motility in 72 hpf “severe” 
gmppb mutant (n=8 embryos) embryos is significantly worsened compared to wild-type (n=12 
embryos) embryos. However, there are no significant differences in motility between “mild” 
mutants (n=21 embryos) and “severe” mutants. (E) “Severe” gmppb mutants (n=8 embryos) 
exhibit significantly increased MTJ angles compared to “mild” gmppb mutants (n=21 embryos) 
and wild-type (n=12 embryos). (F) MTJ failure is not significantly between wild-type (n=12 
embryos), “mild” gmppb mutant (n=21 embryos), or “severe” gmppb mutant (n=8 embryos) 
embryos (p=0.07 between wild-type and “severe” gmppb mutants). (G) “Severe” gmppb 
mutants (n=8 embryos) exhibit a significantly greater percentage of myotomes with 
degeneration than wild-type (n=12 embryos) or “mild” gmppb mutant (n=21 embryos) embryos. 
Scalebars are 50 micrometers. *p<0.05, **p<0.01, ***p<0.001, ns = non-significant. 
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We next asked if NMJ formation was disrupted in gmppb mutants and if mutants 
exhibited variation in NMJ morphology. We analyzed NMJ structure at 72 hpf by staining for 
presynaptic synaptic vesicle protein (SV2) and postsynaptic acetylcholine receptors (alpha-
bungarotoxin), focusing on innervation of fast-twitch fibers (distributed innervation, Fig. 3.4). 
Despite disruptions in initial motor axon development, gmppb embryos still formed synapses 
(Fig. 3.4I-J4). In contrast to wild-type embryos, gmppb “mild” and “severe” mutants exhibited 
reduced distributed innervation within the myotome (Fig. 3.4H-J4). We used a semi-automated 
MATLAB protocol (Chapter 5, Section 5.10.8) to quantify the degree of distributed innervation. 
We found that skeleton length was reduced in both classes of gmppb mutants compared to 
wild-type embryos; however, there were no significant differences between “mild” and “severe” 
gmppb embryos. On average, “mild” gmppb mutant skeleton length was 49.2% of that of the 
wild-type, and “severe” gmppb mutant skeleton length was 49.1% that of the wild-type (Fig. 
3.4K). Taken together these results suggest that although NMJ morphology is disrupted in 
gmppb mutants, NMJs are not significantly different between “mild” and “severe” mutants. 
3.2.5 Gmppb mutants can be quantitatively separated into mild and severe phenotypes 
  The above data suggest that gmppb mutants have “mild” and “severe” phenotypes that 
exhibit significant differences in terms of fiber degeneration and MTJ angles. However, it is key 
to classify the phenotypic severity of gmppb mutants with a non-biased approach. To achieve 
this, we captured birefringence images of wild-type and gmppb mutant embryos at 2 dpf and 
calculated the percent area and percent mean gray value (MGV) (Berger et al., 2012) relative to 
wild-type embryos at this stage. We found that gmppb mutants can be quantitatively separated 
into mild and severe phenotypes (Fig. 3.5) based on their percent area of birefringence  
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Figure 3.4. Gmppb mutants exhibit neural phenotypes. (A-C1) Anterior left, dorsal-top side-
mounted 24 hpf embryos stained for znp-1 (white) labeling primary motoneurons. (A-A1) Wild-
type embryos. Note how primary motor axons extend past the choice point (white arrow). (B-
B1) gmppb mutant embryos predicted to be “mild”. Some primary motor axons are truncated 
and do not extend past the choice point (yellow arrowhead). (C-C1) gmppb mutant embryos 
predicted to be “severe”. Note that many motor axons are truncated. (D) A significantly lower 
percentage of 24 hpf gmppb mutant motor axons (n=29 embryos) exit the spinal compared to 
wild-type (n=27 embryos) embryos. (E) Axon length to the choice point is not significantly 
different between 24 hpf wild-type (n=93 axons) and gmppb mutant (n= 115 axons) embryos. (F) 
The percent of axons that extend past the choice point is significantly lower in 24 hpf gmppb 
mutant (n=15 embryos) than in wild-type (n=13 embryos) embryos. (G) The length of axons that 
extend past the choice point does not significantly differ between wild-type (n=45 axons) and 
gmppb mutant (n=21 axons) embryos. (H-J4) Anterior left, dorsal top, side-mounted embryos 
labeled with acetylcholine receptors (AChRs) and synaptic vesicle protein 2 (SV2). (Lettered 
panels) Merged channels of AChR and SV2. (1) Skeletonized images. (2) Magnification of AChR 
channel. (3) Magnification of SV2 channel. (4) Magnification of skeletonized image. (H-H4) 
Control embryo. (I-I4) “Mild” gmppb mutant embryo exhibiting a reduced degree of distributed 
innervation within the myotome. (J-J4) “Severe” gmppb mutant embryo exhibiting reduced 
distributed innervation within the myotome. (K) Percent of wild-type skeleton length per muscle 
segment in wild-type (n=72 half-myotomes) and gmppb mutant (“mild” n=78 half-myotomes; 
“severe” n=106 half-myotomes) embryos. These percentages are significantly lower in both 
classes of gmppb mutants compared to wild-type but are not significantly different between 
either class of mutants. Scalebars are 50 micrometers. Error bars in (K) are standard error of the 
mean (L). *p<0.05, **p<0.01, ***p<0.001, ns= non-significant. 
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(Fig. 3.5D) and percent MGV (Fig. 3.5E). In mild gmppb mutants, both of these values were 85% 
or higher (see Chapter 5, Section 5.10.2). These results suggest that in terms of muscle, gmppb 
mutants exhibit phenotypic variation that is similar to the variability that is in patients with 
GMPPB-associated dystroglycanopathy.  
3.2.6. A portion of severe gmppb mutants recover to milder phenotypes 
  Gmppb mutant embryos exhibit phenotypic variation in terms of muscle degeneration 
and MTJ angles (Fig. 3.3E, G) and can be quantitatively separated into mild and severe 
phenotypes based on birefringence image analysis at 2 dpf (Fig. 3.5). As this variation is 
detectable at an early stage in life, we asked if such variation in gmppb mutants persists into the 
early larval stages. We performed longitudinal birefringence assays and analyzed birefringence 
images of wild-type and gmppb mutant zebrafish at 2 dpf and 7 dpf (Fig. 3.6A-D4). Surprisingly, 
by 7 dpf, a portion of gmppb mutants that initially had severe phenotypes presented with mild 
phenotypes (Fig. 3.6C-C4, F-I). The average percent area in severe-mild gmppb mutants 
increased to levels similar to those of mild gmppb mutant and wild-type zebrafish at 7 dpf (Fig. 
3.6H). Between 2 dpf and 7 dpf, the average severe-mild gmppb mutant percent MGV 
increased, whereas the average percent MGV of gmppb mutants that remained severe 
decreased (Fig. 3.6I). The reverse of this was rare: we only observed two embryos/larvae that 
had a mild phenotype at 2 dpf that were severe at 7 dpf (one embryo/larva was just under the 
threshold, data not shown). Taken together, these results suggest that gmppb mutants exhibit 
phenotypic plasticity throughout the first several days of life.  
3.3. Discussion 
  Individuals with GMPPB-associated dystroglycanopathy present with a broad range of 
symptoms that vary in terms of age of onset, severity, and involvement of the nervous system. A  
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Figure 3.5. Gmppb mutants can be quantitatively separated into mild and severe phenotypes 
at 2 dpf. (A-C1) Anterior left, dorsal top, side-mounted 2 dpf embryos imaged live for brightfield 
(lettered panels) and birefringence (numbered panels). (A-A1) Control embryo. (B-B1) Mild 
gmppb mutant embryo. Note abnormal tail morphology (black arrowhead). (C-C1) Severe 
gmppb mutant embryo. Note abnormal tail morphology (black and white arrowheads) and 
segments with reduced brightness. (D) Quantification of the percent area of birefringence for 2 
dpf control (n=71 embryos), mild, (n=50 embryos) and severe (n=60 embryos) gmppb embryos. 
There is not a significant difference in the percent area of birefringence between controls and 
mild gmppb mutants. Severe gmppb mutant embryos have a significant reduction in the percent 
area of birefringence compared with mild gmppb mutants and control embryos. (E) 
Quantification of percent mean gray value (MGV) for 2 dpf wild-type (n=71 embryos), mild 
(n=50 embryos), and severe (n=60 embryos) gmppb embryos. Severe gmppb mutant embryos 
have a significant reduction in the percent MGV compared with mild gmppb mutants and 
controls. *p<0.05, **p<0.01, ***p<0.001, ns= non-significant. 
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major gap in our understanding of GMPPB-associated disorders is how one mutated GMPPB 
allele can result in multiple phenotypes. Using CRISPR/Cas9 mutagenesis, we designed a gmppb 
mutant zebrafish line to investigate the mechanisms underlying phenotypic variation in GMPPB- 
associated dystroglycanopathy. To our knowledge, this is the first animal model of this condition  
that has been engineered at the genomic level. In contrast to previous studies in our lab 
regarding NAD+ and dystroglycanopathy, NAD+ supplementation failed to rescue gmppb 
mutants. We found that 72 hpf gmppb mutants exhibit phenotypic variation. Specifically, we 
showed that embryos appearing more severe had significant differences in MTJ angles and fiber 
degeneration compared to milder embryos. We uncovered a novel defect in motor axon 
development in 24 hpf gmppb mutants. Although we detected NMJ abnormalities in gmppb 
mutants, these were not significantly variable between “mild” and “severe” mutants. At 2 dpf, 
we detected mild and severe gmppb mutant phenotypes based on birefringence image analysis. 
Longitudinal studies revealed that gmppb mutants exhibited phenotypic plasticity. Our data 
indicate that zebrafish gmppb mutants exhibit a spectrum of phenotypic variation similar to that 
of human populations. This suggests that gmppb mutant zebrafish are a suitable model for 
studying the mechanisms underlying phenotypic variation in GMPPB-associated 
dystroglycanopathy. 
3.3.1. Alternative splicing in gmppb mutants 
  Gmppb morphant zebrafish have been superficially characterized at 48 hpf and possess 
abnormal muscle structure, curved tails, motility defects, smaller body size, and smaller eyes 
(Carss et al., 2013). There are currently no other published animal models of GMPPB-associated 
dystroglycanopathy. Here, we showed that gmppb mutant zebrafish engineered via CRISPR/Cas9 
mutagenesis exhibit abnormal tail morphology, as well as MTJ failure and muscle degeneration 
(Fig. 3.1). Preliminary RNA-seq analysis revealed that gmppb mutants have an insertion near the  
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Figure 3.6. A portion of severe gmppb mutants recover to mild phenotypes by 7 dpf. (A1-D4) 
Anterior left, dorsal top, side-mounted embryos and larvae live-imaged for brightfield (1-2) and 
birefringence (3-4) at 2 dpf (odd panels) and 7 dpf (even panels). (A1-A4) Control embryo/larva. 
(B1-B4) Mild gmppb mutant embryo/larva. (C1-C4) Severe-mild gmppb mutant embryo/larva. 
(D1-D4) Severe gmppb mutant embryo/larva. Note abnormal posterior morphology (white 
arrowhead) in 7 dpf larva. (E) Legend for (F-I) graphs for control (black), mild (dark blue), severe-
mild (teal) and severe (light blue) larvae. (F) Quantification of percent area of birefringence 
between control (n=51 larvae), mild (n=28 larvae), severe-mild (n=15 larvae), and severe (n=18 
larvae) larvae at 7 dpf. Percent area is significantly lower in severe larvae compared to all other 
groups. (G) Quantification of percent mean gray value (MGV) between control (n=51 larvae), 
mild (n=28 larvae), severe-mild (n=15 larvae), and severe (n=18 larvae) larvae at 7 dpf. Severe 
larvae have a significant reduction in percent MGV compared to all other groups. (H) Average 
percent area of birefringence between control, mild, severe-mild, and severe larvae at 2 dpf and 
7 dpf. Severe-mild gmppb mutant percent area is above 85% at 7 dpf, whereas severe gmppb 
mutant percent area remains below 85% on average. (I) Average percent MGV between control, 
mild, severe-mild, and severe embryos at 2 dpf and 7 dpf. Severe-mild gmppb mutant percent 
MGV is higher at 7 dpf than at 2 dpf, whereas severe gmppb mutant percent MGV is lower at 7 
dpf than at 2 dpf on average. Since data are only shown for 2 dpf and 7 dpf, a linear relationship 
should not be assumed for the data presented in (H) and (I). Error bars in (H) and (I) are 
standard error of the mean, *p<0.05, **p<0.01, ***p<0.001, ns= non-significant. 
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end of intron 2 and have mis-spliced gmppb transcripts in addition to correctly spliced 
transcripts. Four classes of mis-spliced variants were detected (Appendix B). Three of these 
variants have been predicted to shift the reading frame and result in premature stop codons in 
the protein sequence (Fig. 3.1, Appendix B). This hypomorphic mutant is well-suited to study the 
basic biological mechanisms in the context of GMPPB-associated dystroglycanopathy. 
  Gmppb mutant zebrafish exhibiting RNA mis-splicing are just one example of alternative 
splicing in the context of neuromuscular disease. Alternative RNA splicing has been reported in 
the context of MDC1A (Kemaladewi et al., 2017; Sunada et al., 1995), Fukuyama Congenital 
Muscular Dystrophy (Taniguchi-Ikeda et al., 2011), molecular variants of Duchenne and Becker 
Muscular Dystrophies (Béroud et al., 2004; Takeshima et al., 2010; Todeschini et al., 2016) and 
Limb-Girdle Muscular Dystrophy Type 1B (LGMD1B) (Ito et al., 2017; Luo et al., 2014) (reviewed 
by (Montes et al., 2019; Scotti and Swanson, 2016)). LGMD1B is associated with LMNA 
mutations. Depending on the molecular basis of the LMNA mutation, individuals can also 
develop other conditions, including Emery-Dreifuss Muscular Dystrophy (EDMD), progeria 
syndromes, and lipodystrophy (Scotti and Swanson, 2016). Gmppb mutants have multiple 
classes of incorrectly spliced gmppb reads and exhibit phenotypic variation; thus, it would be 
interesting to determine whether different phenotypic classes of gmppb mutants have different 
mis-spliced gmppb reads.  
3.3.2 Cell-matrix adhesion and GMPPB-associated dystroglycanopathy 
 Muscle fibers must adhere to the myotendinous junction (MTJ) for proper development 
and homeostasis. We previously identified a pathway that contributes to this process and 
determined that Nrk2b-mediated NAD+ synthesis drives laminin organization at the MTJ during 
zebrafish muscle development (Goody et al., 2010). We subsequently showed that NAD+ 
supplementation is sufficient to improve laminin organization, muscle structure, and muscle 
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function in the absence of either DG or Itga7 (Goody et al., 2012), or in the absence of Fkrp 
(Chapter 2). Based on this information, we hypothesized that NAD+ would be sufficient to 
improve muscle structure in gmppb mutants. Surprisingly, we found that NAD+ supplementation 
prior to muscle development is not sufficient to improve muscle in gmppb mutant embryos. We 
subsequently found that beta-DG fails to localize to the terminal ends of individual gmppb 
mutant muscle fibers and is mislocalized along the myofibers.  
 DG clustering is highly variable among patients with GMPPB-associated 
dystroglycanopathy (Bharucha-Goebel et al., 2015; Cabrera-Serrano et al., 2015; Jensen et al., 
2015; Oestergaard et al., 2016). A recent study has suggested that beta-DG may also be a 
marker of disease and determined that the mobility of beta-DG shifts on Western blots 
analyzing this protein in a subset of patients with GMPPB-associated dystroglycanopathy and 
that GMPPB is required for N-linked glycosylation of beta-DG (Sarkozy et al., 2018). This is not 
surprising, given that beta-DG contains 1 N-linked glycosylation site (Barresi and Campbell, 
2006). N-glycans are also found on all integrin heterodimers (Janik et al., 2010) and cleavage of 
N-linked glycans on Integrinalpha5beta1 prevents its binding to fibronectin in the ECM (Zheng et 
al., 1994). It is currently unknown whether N-glycosylation of integrins promotes either laminin 
binding affinity or membrane localization of Integrinalpha6beta1 or Integrinalpha7beta1. 
Determining whether GMPPB and/or N-glycosylation are necessary for either of these processes 
to occur would be an interesting avenue to explore in the future. 
3.3.3. Primary motoneuron disruption in GMPPB-associated dystroglycanopathy 
 Dystroglycan (DG) is associated with the NMJ through the utrophin glycoprotein 
complex (Deconinck et al., 1997). Thus, it is not surprising that NMJ morphology is disrupted in 
dystroglycanopathies. Fukutin- and Large- deficient mice have abnormal NMJs shortly after birth 
(Herbst et al., 2009; Saito et al., 2007). In Chapter 2, we show that NMJ development is 
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disrupted in fkrp morphants at 3 dpf (Fig. 2.5, 2.6). Congenital myasthenic syndrome, a disease 
that affects neuromuscular transmission at the NMJ, has been documented in patients with 
GMPPB-associated dystroglycanopathy (Belaya et al., 2015; Luo et al., 2017; Rodríguez Cruz et 
al., 2016). However, it is unclear when exactly NMJ development becomes disrupted. Early in 
development, primary motoneurons exit the spinal cord and innervate myotomes (Panzer et al., 
2005). Here, we showed that primary motoneuron development is disrupted in gmppb mutant 
zebrafish at 24 hpf. To our knowledge, we are the first to report this in the context of 
dystroglycanopathy. Several ECM proteins implicated in various stages of motoneuron 
development are glycosylated, including plexin3A, collagen XV, collagen XIII, and sema5a 
(Feldner et al., 2007; Guillon et al., 2016; Hilario et al., 2009; Schneider and Granato, 2006). 
Therefore, it is possible that some of these ECM components have altered glycosylation and/or 
function in gmppb mutants. We found that a lower percentage of motor axons exit the spinal 
cord in gmppb mutants (Fig. 3.4D). We hypothesize that impaired glycosylation of one or more 
of the aforementioned guidance proteins could inhibit motor axon growth in gmppb mutants. 
Specifically, we would test whether expression and/or localization of any of these guidance 
proteins are altered in gmppb mutant embryos and if levels of abnormal expression and/or 
localization correlate with mild and severe phenotypes detected via birefringence. 
 Although early motoneuron defects and disrupted NMJ morphology are present, we 
also showed that synapses still form in gmppb mutants (Fig. 3.4H-J). Although NMJ morphology 
was disrupted in gmppb mutants, we did not detect any significant differences in skeleton 
length between “ mild” and “severe” gmppb mutant embryos. These results were somewhat 
surprising, given the range of variability we observed in primary motor axon phenotypes in 
gmppb mutants (Fig. 3.4). In the future, it will be interesting to determine if NMJ formation in 
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gmppb mutants is facilitated by recovery of primary motor axon pathfinding, compensatory 
secondary axon pathfinding, or cycles of regeneration following degeneration.  
3.3.4. Phenotypic variation and plasticity in gmppb mutants  
 Phenotypic variation is common in neuromuscular diseases, including GMPPB-
associated dystroglycanopathy. Although genotype-phenotype correlations are starting to 
emerge, individuals still present with a broad spectrum of symptoms and severities. This is 
especially true for the c.79 G>C variant associated with Limb-Girdle Muscular Dystrophy Type 2T 
(LGMD2T) and Congenital Myasthenic Syndrome. Individuals with this specific mutation have 
highly variable symptoms and ages of onset (Bharucha-Goebel et al., 2015; Cabrera-Serrano et 
al., 2015; Carss et al., 2013; Jensen et al., 2015; Montagnese et al., 2017; Oestergaard et al., 
2016; Raphael et al., 2014). We currently do not understand how individuals with the same 
mutant allele can experience drastically different symptoms and severities. Gmppb mutants 
exhibited a similar degree of phenotypic variation. These embryos can be categorized into mild 
and severe phenotypes based on birefringence image analysis at 2 dpf. By 7 dpf, a portion of 
gmppb mutants initially presenting with severe phenotypes recovered to milder phenotypes. 
Conversely, we only observed two gmppb mutants initially presenting as mild that became 
severe by 7 dpf (one was just under the threshold). Our data do not resolve the mechanisms 
underlying phenotypic variation and plasticity in this model. We hypothesize that this 
phenotypic variation is driven by one or more distinct molecular and/or cellular mechanisms. 
Several potential mechanisms include differences in RNA mis-splicing, muscle regeneration 
and/or degeneration, motor axon pathfinding, and cell adhesion strength (detailed in Chapter 
4). These future studies aim to provide insight regarding the cell behaviors underlying 
phenotypic variation and plasticity in gmppb mutants. 
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3.4. Conclusion 
Phenotypic variation is common in many neuromuscular disorders, including the 
dystroglycanopathies. We took advantage of CRISPR/Cas9 technology to engineer a zebrafish 
model of GMPPB-associated dystroglycanopathy, a neuromuscular disorder with highly variable 
clinical presentation. We found that the gmppb mutant allele is hypomorphic and mutants 
present with alternatively spliced gmppb RNA reads. Gmppb mutants also exhibited abnormal 
muscle and MTJ structure. In contrast to previous studies concerning other zebrafish models of 
dystroglycanopathies, these attributes are not improved with NAD+ supplementation prior to 
muscle development. We found that at 72 hpf, gmppb mutants exhibited “mild” and “severe” 
phenotypes, particularly in regard to muscle degeneration and MTJ angles. Although 
motoneuron development and NMJ morphology were abnormal in gmppb mutants, we did not 
find significant differences in NMJ morphology between “mild” and “severe” gmppb mutants. 
We determined that gmppb mutants can be quantitatively separated into mild and severe 
phenotypes at 2 dpf. Longitudinal birefringence imaging revealed that a portion of gmppb 
mutants initially presenting with severe phenotypes presented with milder phenotypes by 7 dpf. 
Taken together, our data indicate that gmppb mutants are well-suited to study the molecular 
and cellular behaviors underlying phenotypic variation in dystroglycanopathies.  
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CHAPTER 4 
FUTURE DIRECTIONS 
4.1. Introduction  
 The journey to elucidating the developmental and cellular behaviors evident in 
dystroglycanopathies is far from complete. While the work described herein has provided 
valuable insight regarding neuromuscular development and phenotypic variation in these 
conditions, it has also led to new and important questions. This chapter provides examples of 
exciting future directions to explore regarding zebrafish models of dystroglycanopathy. The 
following experiments are only a microcosm of possibilities. Other potential areas of exploration 
that will not be discussed in this chapter include the design of humanized gmppb mutant 
zebrafish, determining whether ECM proteins that participate in motoneuron guidance are 
impaired in gmppb mutants, elucidating intrinsic compensatory mechanisms present in gmppb 
mutants, and longitudinal studies of zebrafish models of FKRP-associated dystroglycanopathy. It 
is important to note that our preliminary experiments analyzing muscle and NMJs should be 
repeated with gmppb mutants that have been classified as mild or severe via birefringence 
analysis and should be repeated with a larger sample size. It is also essential to determine the 
exact molecular basis of gmppb mutants, particularly the genomic DNA sequence of intron 2. 
4.2. New zebrafish models of FKRP-associated dystroglycanopathy 
Zebrafish embryos have been advantageous in determining the cellular and molecular 
mechanisms governing disease phenotypes in muscular dystrophies, including 
dystroglycanopathies. While fkrp morphants are a respectable model for exploring FKRP-
associated dystroglycanopathy, it would be useful to leverage novel fkrp mutant zebrafish in 
future research projects. Repeating experiments described in Chapter 2, especially NAD+, 
laminin, and NMJ experiments, with fkrp mutant zebrafish is ideal in order to confirm that our 
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observations also occur in fkrp mutants. Second, these models would be important for 
performing any longitudinal studies regarding FKRP-associated dystroglycanopathy in zebrafish, 
as the efficacy of morpholinos fades by 5 dpf. 
Our lab has recently obtained two fkrp mutant zebrafish models (kind gifts from Dr. 
James Dowling and Dr. Matthew Alexander). One of these mutants is listed in the Sanger 
database contains a single nucleotide substitution which results in a premature stop codon at 
amino acid 169 (Kettleborough et al., 2013) but remains uncharacterized. The additional model 
we obtained contains a 13 bp deletion generated by TALENs and also carriers a heat-shock 
inducible promoter for human FKRP carrying the L276I mutation (Serafini et al., 2018). When 
heat-shocked, this line exhibits a milder phenotype (Serafini et al., 2018). These mutant lines 
would be ideal to use for future studies regarding FKRP-associated dystroglycanopathy. 
4.3. What are the tissue-specific requirements of Fkrp? 
 In Chapter 2, we determined that muscle-specific overexpression of Fkrp improved MTJ 
morphology; however, it was not sufficient to improve fiber resiliency and mobility in fkrp 
morphant zebrafish. Given that previous studies demonstrated that this enzyme resides in the 
perinucleus, sarcolemma, and Golgi cisternae (Alhamidi et al., 2011) and that muscle-specific 
expression of LARGE improves muscle pathology in large mutant mice (Gumerson et al., 2013), 
these results are surprising and intriguing. Our work is the first to indicate that Fkrp is required 
outside of muscle fibers for normal muscle development and homeostasis.  
 We also showed that Fkrp in zebrafish is required for homeostasis of two specialized 
muscle junctions that are necessary for proper muscle function: the myotendinous junction 
(MTJ) and the neuromuscular junction (NMJ). These interfaces link muscle with tendons and 
motoneurons, respectively. We speculate that Fkrp activity may be required in tendons and/or 
motoneurons, either independently or concurrently with activity in muscle, for proper MTJ and 
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neuromuscular development. Experiments that take advantage of additional tissue-specific 
promoters are an important first step in determining the tissue-specific requirements of Fkrp. 
We would drive Fkrp expression under motoneuron-specific promoters such as mnx:1 (primary 
motoneurons) (Zelenchuk and Brusés, 2011) or gata2 (secondary motoneurons) (Meng et al., 
1997) and a tenocyte-specific promoter such as scxa (Chen and Galloway, 2014) and perform 
experiments with transgenics similar to those described in Chapter 2. These promoters would be 
fused to non-GFP fluorophores such as mCherry or mKate in order to create double transgenics 
in which Fkrp is overexpressed simultaneously in multiple tissues. If any of these combinations 
of tissue-specific overexpression rescued mobility or fiber degeneration in fkrp morphants or 
mutants, it would suggest that Fkrp is sufficient in those tissues for proper muscle development 
and homeostasis. Generating tissue-specific fkrp mutants to determine where Fkrp is necessary 
for proper muscle development and homeostasis is another possible avenue to explore. 
Experiments that elucidate the tissue-specific roles of Fkrp are key for providing insight for 
clinical researchers considering gene therapy as an avenue for improving muscle disease in 
patients with FKRP-associated dystroglycanopathy. 
4.4. Functional rescue of gmppb mutants 
 When a novel genetic mutant is generated with a clear phenotype, it is important to 
determine if that mutant can be improved via mRNA rescue or chemical interventions. Injection 
of mRNA constructs designed to induce overexpression of Gmppb is one approach. Several 
transgenic gateway constructs designed for this purpose are currently under construction. These 
include Tg(bact2:gmppb-EGFP) and Tg(hsp70l:gmppb-EGFP). These vectors can be injected into 
1-cell stage gmppb mutant embryos. We would expect Tg(bact2:gmppb-EGFP) embryos to 
constitutively express Gmppb-EGFP without the need for additional manipulation. 
Tg(hsp70l:gmppb-EGFP) embryos would require heat shock at 38°C for 2 hours during an early 
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developmental stage (likely 15 somites or earlier, see Chapter 2) to induce Gmppb-EGFP 
expression. Successfully injected embryos would be raised to adulthood, and transgenic F1 
progeny will be used for subsequent experiments. One outcome is that Gmppb-EGFP expressing 
embryos would exhibit improved muscle phenotypes. However, this approach might not rescue 
gmppb mutant phenotypes because our gmppb mutants are splice mutants. 
 An alternative method for rescuing gmppb mutants is to supplement embryos with 
exogenous GDP-mannose. Previous studies demonstrated that mannose supplementation 
improved phenotypes in cultured fibroblasts from individuals with congenital disorders of 
glycosylation (Rush et al., 2000). GMPPB synthesizes GDP-mannose from mannose-1-phosphate 
(Fig. 3.1A; (Carss et al., 2013)); therefore, we hypothesize that exogenous GDP-mannose can 
restore functional glycosylation to gmppb mutants. We would supplement gmppb mutants at 
several developmental stages with GDP-mannose in a manner similar to NAD+ supplementation. 
Designing experiments this way would allow us to determine if GDP-mannose supplementation 
is necessary prior to muscle development in gmppb mutants. Additionally, it would be 
interesting carry out these experiments longitudinally to determine if GDP-mannose repletion 
after muscle development gradually improves phenotypes in gmppb mutations. If GDP-mannose 
repletion experiments successfully rescued gmppb mutants, these results would have 
translational implications as a potential therapeutic for patients with GMPPB-associated 
dystroglycanopathy.    
4.5. Elucidating the mechanisms underlying phenotypic variation in gmppb mutants 
 In Chapter 3, we showed that gmppb mutant zebrafish exhibit phenotypic variation. 
Gmppb mutants presenting with more “severe” phenotypes (not classified by birefringence 
image analysis) on average exhibited greater degrees of muscle degeneration. We also found 
that primary motor axon pathfinding was disrupted in gmppb mutants at 1 dpf (Fig. 3.4A-C). We 
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determined that gmppb mutants can be quantitatively classified as mild or severe based on 
birefringence image analysis at 2 dpf (Fig. 3.5) and that a portion of gmppb mutants initially 
presenting with severe phenotypes recover to mild phenotypes by 7 dpf (Fig. 3.6). These results 
beget the question of how these phenotypes, and their variability, originate in gmppb mutants. 
Such variation could occur via several mechanisms at the molecular and cellular levels (Fig. 4.1) 
and will be discussed in the following subsections. 
4.5.1. Do levels of RNA mis-splicing correlate between mild and severe gmppb mutant 
phenotypes?  
The gmppb mutant zebrafish described in Chapter 3 have an insertion in intron 2 that 
leads to alternative RNA splicing. These variants are predicted to generate truncated protein 
products based on the location of the open reading frame (Fig. 3.1A, Appendix B). In Chapter 3, 
we revealed that gmppb mutant zebrafish exhibit mild and severe phenotypes and that a 
portion of mutants initially presenting as severe recover to mild. Although there are likely cell 
behaviors that accompany these observations, it is also critical that we consider the role that 
alternative splicing levels could play in phenotypic variation and plasticity. 
A collaborative study between the labs of Dr. Clarissa Henry and Dr. Benjamin King at 
the University of Maine is currently underway to answer this question. Longitudinal 
birefringence imaging was performed on control and gmppb mutant embryos at 2 dpf, 4 dpf, 
and 7 dpf, and birefringence images were analyzed immediately after each time point. 
Representative control, gmppb mild, and gmppb severe embryos at 4 dpf and 7 dpf were pooled 
together for deep sequencing (RNA-Seq). Data analysis of the deep sequencing data is currently 
in progress. When complete, this study is expected to determine whether levels of incorrectly 
spliced gmppb RNA correlate with mild and severe phenotypes (Fig. 4.1A). Another potential  
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Figure 4.1. Potential mechanisms underlying phenotypic variation in gmppb mutant zebrafish. 
(A) One possible mechanism of phenotypic variation is different levels of RNA mis-splicing of the 
GMPPB transcript between mild and severe mutants. We hypothesize that severe gmppb 
mutants would exhibit higher levels of RNA mis-splicing. (B) It is also possible that mild and 
severe gmppb mutants have differences in regenerative capacity of their muscle. Our hypothesis 
is that severe gmppb mutants experience more muscle degeneration (red arrowhead) than mild 
gmppb mutants (green arrowhead) and that mild gmppb mutants could regenerate muscle. (C) 
We must also consider the possibility that the severity of primary motor axon pathfinding 
predicts phenotypic severity in the muscle of gmppb mutants. We hypothesize that severe 
gmppb mutants exhibit more severe disruptions of motor axon pathfinding early in 
development. (D) An additional mechanism to test is whether mild and severe gmppb mutants 
have differences in cell adhesion strength. We hypothesize that mild mutants will have greater 
cell adhesion and fiber resiliency and will be less prone to muscle wasting upon 
electrostimulation.  
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Figure 4.1.   
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outcome of this study is that different gmppb RNA splice variants correspond with different 
phenotypic classes of gmppb mutants. 
4.5.2. Examining differences in muscle regeneration in gmppb mutants 
 In Chapter 3, we found that gmppb mutant zebrafish exhibit mild and severe 
phenotypes based on birefringence image analysis at 2 dpf (Fig. 3.5). Additionally, we showed 
that gmppb mutants that appear “severe” exhibit a greater degree of muscle degeneration than 
those that do not. A birefringence experiment that examined embryos on a day-by-day basis 
found that while severe gmppb mutants experienced more muscle degeneration, mild gmppb 
mutants with muscle degeneration experienced recovery (data not shown). Taken together, 
these data raise the possibility mild and severe gmppb mutants possess differences in 
regenerative capacity. While immunohistochemistry and fixing embryos at various stages can 
provide initial insight into this question, longitudinal birefringence and confocal imaging of 
gmppb mutants is a more ideal approach to address this. These rigorous techniques would also 
allow us to image gmppb mutants earlier than 2 dpf while still accurately classifying their 
phenotypic severity.  
To address questions regarding regeneration in mild and severe gmppb mutants, we 
must cross gmppb mutants with a transgenic line. We would cross gmppb mutants with 
Tg(mylpfa:lyn-cyan, smych1:GFP, myog:H2B:RFP) transgenic fish (a kind gift from Dr. Jared 
Talbot) that label fast-twitch muscle fibers (cyan), slow-twitch muscle fibers (green), and 
myonuclei (red). Next, we would screen for heterozygous carriers that express these transgenes 
of interest. Beginning at 24 hpf, wild-type and gmppb mutant transgenics would be live-imaged 
via confocal microscopy daily. From 2 dpf to 7 dpf, these same fish would be imaged via 
birefringence immediately before confocal imaging. Such rigorous live imaging of muscle fibers 
and myonuclei would allow us to determine whether differences in muscle regeneration and/or 
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degeneration drive phenotypic variation and plasticity in gmppb mutants (Fig. 4.1B). These 
experiments would also allow us to examine other attributes of muscle development and 
homeostasis over time.  
4.5.3. Does early motor axon pathfinding influence phenotypic severity? 
In addition to muscle phenotypes, gmppb mutants also have delayed motor axon 
pathfinding and reduced fast-twitch fiber innervation (Fig. 3.4). Although levels of distributed 
innervation did not significantly differ between gmppb embryos that appeared mild or severe, it 
is still possible that motor axon pathfinding varies between mutants classified as mild or severe 
via birefringence image analysis. A number of ECM molecules that participate in motor axon 
pathfinding are glycosylated (Feldner et al., 2007; Guillon et al., 2016; Hilario et al., 2009; 
Schneider and Granato, 2006). Therefore, levels of primary motor axon pathfinding early in 
development is another potential mechanism underlying phenotypic variation in gmppb 
mutants. To answer this question, we can identify gmppb mutants crossed with Tg(mylpfa:lyn-
cyan, smych1:GFP, myog:H2B:RFP) transgenic fish that only carry Tg(mylpfa:lyn-cyan) and 
establish a Tg(mylpfa:lyn-cyan);gmppb mutant line. Embryos from this line would be injected 
with transgenic mnx1:mKate (Gribble et al., 2018) and gata2:GFP (Meng et al., 1997) constructs 
in order to also study motor axon pathfinding in gmppb mutants. These embryos would be 
imaged via confocal microscopy daily beginning at 24 hpf, and for birefringence daily beginning 
at 48 hpf. These experiments would allow us to longitudinally image motoneurons in gmppb 
mutants and determine if differences in motor axon pathfinding, neurodegeneration, or 
compensatory innervation mechanisms drive phenotypic variation in gmppb mutants (Fig. 4.1C). 
We are especially interested in determining if levels of motor axon pathfinding influence muscle 
architecture or muscle degeneration and/or regeneration.  
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4.5.4. Investigating differences in cell adhesion strength 
 Our results presented in Chapter 3, particularly regarding fiber detachment, suggest that 
differences in cell-matrix adhesion may exist between mild and severe gmppb mutants. In 
zebrafish, muscle fibers can detach either due to sarcolemmal damage or detachment from the 
MTJ prior to sarcolemmal damage (Hall et al., 2007). A preliminary experiment that used Evan’s 
Blue Dye (EBD) to examine this in gmppb mutants found that fibers primarily detach from the 
MTJ prior to loss of sarcolemmal integrity (data not shown). This suggests that cell-ECM 
adhesion is disrupted in gmppb mutants; thus, it would be useful to determine if gmppb 
mutants exhibit variability in terms of cell adhesion strength.  
 Questions regarding this topic in gmppb mutants can be approached in multiple ways. 
One straightforward approach involves using electrostimulation to test cell adhesion strength. 
This technique has been previously used in zebrafish to induce muscle contraction and to test 
muscle strength (Subramanian and Schilling, 2014) and can be employed to determine whether 
severe gmppb mutants experience greater fiber loss than mild gmppb mutants when stimulated 
(Fig. 4.1D). We plan to perform experiments where control, mild, and severe gmppb embryos 
are imaged for birefringence at 2 dpf. Embryos will immediately receive two rounds of 
electrostimulation followed by subsequent birefringence imaging, and we will determine 
whether severe gmppb mutant embryos experience a greater reduction in birefringence after 
two rounds of electrostimulation than mild gmppb mutant embryos. If this were the case, this 
outcome would suggest that severe gmppb mutants have reduced cell adhesion and fiber 
resiliency compared to mild gmppb mutants. Fixing and staining embryos for phalloidin and for 
cell adhesion/MTJ markers such as laminin after electrostimulation should also be considered in 
when performing these experiments.  
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4.6. Concluding remarks 
 This dissertation highlights the importance of viewing dystroglycanopathies as individual 
conditions. Specifically, our work suggests that this mindset is important in regard to distinct 
dystroglycanopathy genes and the same dystroglycanopathy gene. The experiments described in 
this chapter are designed to elucidate the mechanisms of disrupted neuromuscular 
development, cell-matrix adhesion, and phenotypic variation in dystroglycanopathies. Research 
regarding the tissue-specific requirements of Fkrp will determine where Fkrp is required for 
neuromusculoskeletal development and homeostasis. Analysis of RNA-seq data examining mild 
and severe gmppb mutant phenotypes, cell adhesion experiments, and longitudinal studies 
involving both birefringence and confocal microscopy will yield valuable information regarding 
the molecular and cellular mechanisms that contribute to phenotypic variation and plasticity in 
the context of dystroglycanopathy. As mentioned, there are many additional approaches to 
teasing apart these mechanisms. Studies that incorporate different perspectives and examine 
these conditions at the molecular and cellular levels have the greatest potential to broaden our 
understanding of dystroglycanopathies and provide insight for other basic researchers, 
translational scientists, clinicians, and patients and their families. 
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CHAPTER 5 
MATERIALS AND METHODS 
5.1. Zebrafish husbandry and lines 
5.1.1. Zebrafish husbandry  
All embryos were obtained from natural spawnings of adult zebrafish maintained on a 
14 hour light/10 hour dark cycle at 28.5°C. Embryos were reared in 1X Embryo Rearing Medium 
(ERM) with methylene blue and staged according to (Kimmel et al., 1995). The following strains 
were utilized/generated: AB, Tg(fli1:EGFP) (Lawson and Weinstein, 2002), Tg(ef1α:xbp1δ-GFP) 
(Li et al., 2015) (a kind gift from Dr. Shao Jun Du), Tg(hsp70l:pxn-EGFP) (Coffey et al., 2018), 
Tg(hsp70l:fkrp-EGFP), and Tg(-503unc:fkrp-EGFP). 
5.1.2.  Construction of new transgenic lines 
The Tg(hsp70l:fkrp-EGFP) and Tg(-503unc:fkrp-EGFP) lines were generated via the 
gateway cloning system. A sequence surrounding the fkrp gene was amplified with NCBI-verified 
primers was gated and inserted into the pDONR221 vector (Invitrogen). The heat shock gateway 
222 5’ vector, GFP gateway 366 3’ vector, and the gateway 394 destination vector (Kwan et al., 
2007) were used along with the donor vector and LR clonase II for the Tg(hsp70l:fkrp-EGFP) line. 
Components remained the same for the Tg(-503unc:fkrp-EGFP) line with the exception of the -
503unc zebrafish muscle-specific promoter (Berger and Currie, 2013), which was used in place of 
the heat shock gateway 222 5’ vector. Plasmids were injected at the single cell stage as 
previously described (Goody et al., 2010). 
5.1.3. Construction of gmppb mutants  
The single guide RNA (sgRNA) targeting the gmppb sequence (NCBI gene ID: 445097) 
was selected using CHOPCHOP (Montague et al., 2014). SgRNA synthesis was performed as 
previously described (Gagnon et al., 2014) with the following modifications. Oligonucleotide 
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annealing reactions were doubled and incubated for 40-60 minutes at 12°C. The sgRNA 
transcription reaction was doubled and synthesized using a MaxiScript Kit, and clean-up was 
performed in 4 µl lithium chloride and 150 µl 100% ethanol. Cas9 mRNA was synthesized as 
previously described (Gagnon et al., 2014). Gmppb sgRNA, Cas9, and a stop-cassette 
oligonucleotide (Table 5.1) were injected into one-cell stage AB embryos. F0 embryos with 
successful stop-cassette insertions were raised to adulthood and crossed to generate F1 
embryos. F1 embryos were raised to adulthood and outcrossed with ABs to generate F2 
embryos. All experiments described in Chapter 3 were performed using spawns of the F2 
generation or later. 
 
Table 5.1. Sequences used to construct gmppb mutants via CRISPR/Cas9 mutagenesis. 
Sequences used to construct gmppb mutants with CRISPR/Cas9 mutagenesis technology. Note 
the target site is not a synthesized nucleotide and that the protospacer adjacent motif (PAM) 
sequence is underlined. 
Nucleotide or Sequence 
Name 
Sequence 
GMPPB Target Site (not a 
synthesized nucleotide) 
GGACTCCAGCCTGAACACAGAGG 
GMPPB Gene-Specific 
Oligonucleotide 
ATTTAGGTGACACTATAGGACTCCAGCCTGAACACAGGTTTTAGAG 
CTAGAAATAGCAAG 
GMPPB Stop-Cassette 
Oligonucleotide 
ACCATCCAACGGTGCCTCTGGTCATGGCGTTTAAACCTTAATTAAGCT 
GTTGTAGTGTTCAGGCTGGAGTCCGTC 
Left Homology Sequence ACCATCCAACGGTGCCTCTG 
Right Homology Sequence TGTTCAGGCTGGAGTCCGTC 
 
5.2. Morpholino injections 
Antisense MOs were obtained from Gene Tools, LLC, and hydrated at 65°C for 10 
minutes with sterile water to generate 1 mM stocks. For fkrp morphant experiments, the 
previously published fkrp MO2 (5’-CTTGTGGTTTTATGGCAGAAAGAGT-3’) (Kawahara et al., 2010) 
was utilized and injected into the yolk of 1-2 cell stage embryos so that embryos received 
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approximately 3.2 ng of MO. For dag1 morphant experiments, the previously published dag1 
MO (dag1 MO1) (5’-CATGCCTGCTTTTATTTTCCCTCGC-3’ (Parsons et al., 2002) and an additional 
slightly overlapping dag1 MO (dag1 MO2) (5’-CCCTCGCTCGTACAAAAGAGGACGT-3’) were co-
injected into the yolk of 1-2 cell stage embryos so that embryos received approximately 12 ng of 
each dag1 MO1 and dag1 MO2. Embryos utilized in experiments alongside NAD+ and EmergenC 
treated embryos were placed in 60 mm Petri dishes with 25 embryos per dish in 10 mL 1X ERM. 
5.3. NAD+ and EmergenC supplementation 
Embryos receiving EmergenC treatment (Alacer Corp) were separated into 60 mm Petri 
dishes with 25 embryos per dish in 10 mL 1X ERM-EmergenC solution. The NAD+ solution was 
prepared as previously described (Goody et al., 2010) except in sterile water. The EmergenC 
solution was diluted in 1X ERM so that the level of niacin in the solution was equal to 7.61 µM. 
Supplementation began at 6 hpf or 24 hpf depending on the experiment and the solution was 
changed every 24 hours until embryo fixation. 
5.4. Expression of constructs with the heat shock promoter 
To constitutively overexpress Fkrp, uninjected and injected Tg(hsp70l:fkrp-EGFP) 
embryos were heat shocked at 38°C for 1.25-2 hours at the 15 somite stage. To overexpress 
Paxillin, Tg(hsp70l:pxn-EGFP) were heat shocked at 38°C for 1.5 hours at 12 hpf, then for 1.5-2 
hours daily until fixation. Heat-shocked fish were immediately transferred to 28°C.  
5.5. Mobility assays 
To assess mobility in fkrp morphants, touch response analysis was performed at 3 
dpf. Embryos were placed in 1X ERM and stimulated at the posterior end with fishing wire. The 
number of touches to evoke an escape response was recorded. For embryos that did not 
respond after 50 touches, 50 was recorded as their touches to response. Mobility in gmppb 
mutants was assessed as previously described (Goody et al., 2012). 
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5.6. Immunohistochemistry 
All embryos were fixed in 4% Paraformaldehyde (PFA) for 2-4 hours at room-
temperature, depending on the stage. After fixation, embryos received five rinses in PBS-0.1% 
Tween 20. For all embryos not stained with alpha-Bungarotoxin or anti-znp-1, embryos were 
permeabilized for 1.5 hours in PBS-2% Triton-X-100, followed by incubation in 1/20 phalloidin-
546 (Invitrogen) overnight at 4°C. Embryos were then subjected to five rinses for five minutes in 
PBS-0.1% Tween 20, followed by an overnight incubation in antibody block (5%BSA, 1% DMSO, 
1% Triton-X-100, 0.2% saponin in 1X PBS) for embryos receiving subsequent 
immunohistochemistry treatments. Primary antibodies were added at a concentration of 1:50 
(anti-laminin, anti-paxillin, anti-beta-dystroglycan) in antibody block and incubated for 2-8 hours 
at room temperature followed by overnight at 4°C. All embryos were then treated with antibody 
block for 8 hours at room temperature or overnight at 4°C, followed by an overnight incubation 
in 1:200 secondary antibody (GAR488 and GAR633 for polyclonal; GAM488 and GAM633 for 
monoclonal), either preceded or succeeded by a 2-6 hour incubation at room temperature, 
depending on the antibody. Embryos were rinsed out of secondary antibody with PBS-0.1% 
Tween 20 prior to deyolking, mounting, and imaging. 
 NMJ staining was performed as mentioned above with the following changes. After 
rinsing embryos out of 4% PFA, embryos were permeabilized in 1 mg/ml collagenase in 1X PBS 
for 1.25-1.5 hours. Embryos were stained with 1/500 α-Bungarotoxin-647 for 2-4 hours at room 
temperature or overnight at 4°C. For co-staining, 1/20 phalloidin-546 was added to the alpha-
Bungarotoxin solution in antibody block. Embryos were then rinsed as described above. Primary 
SV2 antibody was added at a concentration of 1:50 in antibody block and embryos were 
incubated in this solution for 2-8 hours at room temperature followed by 3 days at 4°C. Staining 
then proceeded as described above. 
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 For anti-znp-1 staining, embryos were rinsed out of PFA as described above. Embryos 
were then dehydrated and rehydrated with methanol (MeOH) with 5 minute incubations (10 
minutes for 100% MeOH) in the following series: 0%, 33%, 66%, 100%, 66%, 33%, 0% MeOH. 
Embryos were immediately blocked in antibody block for 2 hours at room temperature, and 
then were incubated in primary anti-znp-1 antibody at a concentration of 1:50 in antibody block 
overnight at 4°C. Staining then proceeded as described above. 
5.7. Myofiber purification and staining 
 Individual myofibers from control and gmppb mutant zebrafish embryos were purified 
at 48 hpf as previously described (Horstick et al., 2013). Purified myofibers were then fixed in 4% 
PFA for fifteen minutes, rinsed three times for five minutes with PBS-0.1% Tween 20. Myofibers 
were permeabilized for three minutes in PBS-2% Triton-X-100, subsequently rinsed once with 
PBS-0.1% Tween 20, and stained with 1:40 phalloidin-546 in PBS-0.1% Tween 20 overnight at 
4°C. Myofibers were rinsed the following morning three times for five minutes with PBS-0.1% 
Tween 20, were blocked overnight in antibody block at 4°C, then stained for beta-dystroglycan 
overnight at 4°C. Myofibers were rinsed three times for five minutes with PBS-0.1% Tween 20, 
blocked for three hours at room temperature, and then incubated in secondary antibody 
(GAM488) overnight at 4°C. Embryos were then rinsed five times for five minutes with PBS-0.1% 
Tween 20. 
5.8. Imaging 
 For live brightfield and birefringence imaging, embryos were anesthetized in Tricaine, 
placed into a glass-bottomed dish, and imaged on a Leica screening microscope with camera 
attachment. For birefringence images, a polarized light filter attachment was placed onto the 
microscope. All live brightfield and birefringence images were taken at 2.5X and 3.2X. Fixed and 
stained embryos were deyolked, mounted, and imaged in 80% glycerol as previously described 
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(Goody et al., 2012). Fluorescent images of embryos were captured at 20X with a Zeiss Axio 
Imager Z1 microscope with a Zeiss ApoTome attachment, at 20X with an Olympus Fluoview IX-
81 inverted microscope with FV1000 confocal system, or at 25X with a Leica DMi8 confocal 
microscope. Images for Tg(ef1α:xbp1δ-GFP) were acquired at 10X on a Zeiss Axio Imager Z1 
microscope with a Zeiss ApoTome attachment or at 5X on a Zeiss microscope with Vivatome 
attachment. Exposure time was kept consistent between all embryo groups within an 
experiment for Tg(ef1α:xbp1δ-GFP) experiments. 
5.9. Statistical analyses 
All statistical analyses were performed in GraphPad PRISM 8. Quantitative data were log 
transformed before performing statistical comparisons. Statistical comparisons of quantitative 
data were performed using an unpaired two-tailed t-test for comparisons of two groups and an 
ordinary one-way ANOVA with Tukey’s ad-hoc analysis for comparisons of three or more groups. 
Categorical MTJ staining intensity data were analyzed using Fisher’s Exact Test for two 
categories and a Chi Square test for three or more categories. 
5.10. Image analyses 
5.10.1. Birefringence image analysis 
 Birefringence was quantified using FIJI as previously described (Berger et al., 2012) with 
the following modifications. For each experiment, a polygon was drawn around the fish body of 
a birefringence image between myotomes 6 and 26, and the area and mean gray value (MGV) 
were measured. This was repeated three times for each embryo, and the values were averaged. 
The average area and MGV for all controls were subsequently calculated. These values were 
used to determine the percent area and percent MGV for all embryos. Mutants with a percent 
area and a percent MGV at 85% or higher were classified as mild mutants.  
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5.10.2. Phenotypic classification 
Embryos that received only phalloidin and/or NMJ staining (Fig. 3.3, 3.4) were 
retroactively classified as “mild” or “severe,” as these experiments were performed prior to our 
longitudinal studies. We initially planned to use gmppb mutants to study the relationship 
between muscle degeneration, MTJs, and NMJs; however, we observed remarkable phenotypic 
variation in the muscle of gmppb mutants in our confocal images. These observations were the 
basis for the longitudinal studies we conducted. For embryos imaged via birefringence, the 
percent area and MGV values described above were used to determine the phenotypic class of 
gmppb mutant embryos. Mutants with a percent area and a percent MGV at 85% or higher we 
classified as mild mutants. Embryos that did not meet these criteria were classified as severe 
mutants.  
5.10.3. Myotome scoring 
Muscle fiber degeneration was quantified by counting the number of muscle segments 
with degeneration per embryo and calculating the percent of myotomes with muscle 
degeneration. For laminin and beta-DG staining analyses, images were blinded using a Perl script 
and embryos were scored according to their relative staining intensity (Appendix A). 
5.10.4. MTJ angles 
Myotendinous junction angles were analyzed in FIJI (Schindelin et al., 2012; Schneider et 
al., 2012) (Schindelin et al., 2012; Schneider et al., 2012) by using the angle tool. 
5.10.5. Anisotropy analysis 
For anisotropy analysis, a polygon was drawn in eight myotomes per image analyzed 
using the polygonal lasso tool in Adobe Photoshop. The x,y coordinates of each polygon were 
recorded. Masks were generated from the coordinates, and 2DWTMM analysis was performed 
on each of these masks as previously described (Goody et al., 2010; Goody et al., 2012). 
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5.10.6. Fluorescence intensity 
For analysis of xbp1 transgenic embryos, fluorescence intensity was quantified using FIJI. 
A polygon was drawn around the dorsal muscle above the notochord for all embryos in the 
trunk region. The average pixel intensity (mean gray value) was calculated. The mean average 
pixel intensity for all controls was calculated. These values were used to determine the percent 
average pixel intensity for all embryos. Images for all xbp1 transgenic embryos were blinded 
using a Perl script prior to analysis. 
5.10.7. Intersegmental vessel and motoneuron lengths 
 Intersegmental vessel (ISV) lengths and primary motoneuron lengths were measured in 
FIJI using the segmented line tool. 
5.10.8. NMJ analysis 
Confocal images were processed into maximum intensity projections of distributed and 
myoseptal innervation using FIJI. Masks for the fish, horizontal myoseptum, and myoseptal 
innervation were generated in FIJI and were subsequently imported into MATLAB (Mathworks) 
for segmentation of the red (AChR) and green (SV2) fluorescence channels. Adaptive histogram 
equalization (MATLAB “adapthisteq” function) was used to enhance the images, and a 1 pixel 
radius Gaussian filter (MATLAB ‘imguassfilt’ function) was used to denoise the images. A 
threshold of 30 was used on each channel to generate single masks of fluorescence images, 
which were then combined with an or statement. Masks were skeletonized, and then cleaned 
and despurred using the “bwmorph” command in MATLAB. This command was also used to 
identify branchpoints. Muscle segments (half-myotomes) were defined using the masks for the 
fish, horizontal myoseptum, and myoseptal innervation. Measurements of skeleton length and 
branching frequency were then performed for each muscle segment (half-myotome) per 
embryo.  
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5.10.9. Myofiber analysis 
 For myofiber analysis, a polygon was drawn around each individual fiber in FIJI. The total 
area, perimeter, and Feret’s diameter were measured for each individual fiber. The filament 
index (a measure of how much an object’s shape deviates from circular) of the myofibers was 
calculated as previously described (Snow et al., 2008b).  
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APPENDIX A: CATEGORICAL SCORING OF MTJ STAINING INTENSITY 
 
Figure A1. Scoring of relative MTJ staining intensity. (A-C) Anterior left, dorsal-side mounted 
zebrafish embryos at 26 hpf stained for laminin-111 at the MTJ (purple). (A) Example of an 
embryo with strong laminin staining intensity at the MTJ. (B) An embryo with weak laminin 
staining intensity at the MTJ. (C) An embryo lacking laminin staining at the MTJ. 
  
120 
 
APPENDIX B: PRELIMINARY RNA-SEQ DATA OF GMPPB MUTANTS 
The following data are results of a collaboration with Dr. Benjamin King’s laboratory at 
the University of Maine. The Henry laboratory sorted the wild-type and gmppb mutant embryos 
prior to RNA extraction; the King laboratory performed the RNA extraction, sent the samples for 
RNA sequencing, and compiled/analyzed the read data. RNA-seq was performed at the Hubbard 
Center for Genome Studies at the University of New Hampshire. These data indicate the 
presence of alternative splicing and differential gene expression in gmppb mutants. Analysis of a 
second RNA-seq experiment with control, mild gmppb mutants, and severe gmppb mutants is 
currently in progress (Kodey Silknitter and Dr. Benjamin King, personal communication). 
 
Table B.1. RNA-seq reads of gmppb transcripts in gmppb mutants. Four distinct classes of 
splice variants were detected in gmppb mutants. Protein products were predicted using the 
Open Reading Frame (ORF) Viewer Tool. Data provided by Dr. Benjamin King (personal 
communication). 
Category of Read Predicted Protein Product 
Properly spliced (normal) Normal protein product 
Unspliced Currently Unknown 
7 base pair insertion from intron Frameshift with premature stop codon 
at amino acid 59 
8 base pair cassette insertion and 8 base pair 
insertion from intron 
Frameshift with premature stop codon 
at amino acid 58 
24 base pair cassette insertion and 8 base pair 
insertion from intron 
Frameshift with premature stop codon 
at amino acid 47 
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Figure B.1. Examples of RNA-seq reads of gmppb transcripts. (A) Correctly spliced read. (B) 
Mis-spliced read with 7 bp insertion from intron (red box). (C) Mis-spliced read with 8 bp 
cassette insertion (gray box) and 8 bp insertion from intron (red box). (D) Mis-spliced read with 
24 bp cassette insertion (gray and blue boxes) and 8 bp insertion from intron (red box). Exon 2 
sequences are in green font, exon 3 sequences are in blue font. The last base pair of exon 2 and 
first base pair of exon 3 are surrounded by a yellow box. Data provided by Kodey Silknitter and 
Dr. Benjamin King (personal communication). 
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